# Official Journal C 306/2015

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 306 |
| | |
| English edition | Information and Notices | Volume 5817 September 2015 |

ISSN 1977-091X

Official Journal

of the European Union

C 306

English edition

Information and Notices

Volume 5817 September 2015

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2015/C 306/01 | Non-opposition to a notified concentration (Case M.7663 — DTZ/Cushman & Wakefield) (
  1
  ) | 1 |
| 2015/C 306/02 | Non-opposition to a notified concentration (Case M.7738 — Naxicap/Banque publique d’investissement/DEFTA Group) (
  1
  ) | 1 |
| 2015/C 306/03 | Non-opposition to a notified concentration (Case M.7731 — Bpifrance/Springwater/Delion France) (
  1
  ) | 2 |
| 2015/C 306/04 | Non-opposition to a notified concentration (Case M.7751 — CVC Capital Partners SICAV-FIS/PKP Energetyka) (
  1
  ) | 2 |
| 2015/C 306/05 | Non-opposition to a notified concentration (Case M.7730 — Groupe Acticall/Sitel Worldwide Corporation) (
  1
  ) | 3 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2015/C 306/01

Non-opposition to a notified concentration (Case M.7663 — DTZ/Cushman & Wakefield) (
  1
  )

1

1

2015/C 306/02

Non-opposition to a notified concentration (Case M.7738 — Naxicap/Banque publique d’investissement/DEFTA Group) (
  1
  )

1

1

2015/C 306/03

Non-opposition to a notified concentration (Case M.7731 — Bpifrance/Springwater/Delion France) (
  1
  )

1

2

2015/C 306/04

Non-opposition to a notified concentration (Case M.7751 — CVC Capital Partners SICAV-FIS/PKP Energetyka) (
  1
  )

1

2

2015/C 306/05

Non-opposition to a notified concentration (Case M.7730 — Groupe Acticall/Sitel Worldwide Corporation) (
  1
  )

1

3

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2015/C 306/06 | Euro exchange rates | 4 |
| 2015/C 306/07 | Commission Decision of 10 February 2015 on the list of public holidays for 2016 for the institutions of the European Union | 5 |
| | NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA |
| | Standing Committee of the EFTA States |
| 2015/C 306/08 | Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014 | 6 |
| 2015/C 306/09 | Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014 | 24 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2015/C 306/06

Euro exchange rates

4

2015/C 306/07

Commission Decision of 10 February 2015 on the list of public holidays for 2016 for the institutions of the European Union

5

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

2015/C 306/08

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014

6

2015/C 306/09

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014

24

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 17.9.2015 | EN | Official Journal of the European Union | C 306/1 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/1

---

Non-opposition to a notified concentration

(Case M.7663 — DTZ/Cushman & Wakefield)

(Text with EEA relevance)

(2015/C 306/01)

On 27 August 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English language and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7663. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7663. EUR-Lex is the online access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/1 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/1

---

Non-opposition to a notified concentration

(Case M.7738 — Naxicap/Banque publique d’investissement/DEFTA Group)

(Text with EEA relevance)

(2015/C 306/02)

On 9 September 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in French language and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7738. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7738. EUR-Lex is the online access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/2 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/2

---

Non-opposition to a notified concentration

(Case M.7731 — Bpifrance/Springwater/Delion France)

(Text with EEA relevance)

(2015/C 306/03)

On 9 September 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in French language and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes. |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes.

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7731. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7731. EUR-Lex is the on-line access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/2 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/2

---

Non-opposition to a notified concentration

(Case M.7751 — CVC Capital Partners SICAV-FIS/PKP Energetyka)

(Text with EEA relevance)

(2015/C 306/04)

On 9 September 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English language and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7751. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7751. EUR-Lex is the online access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/3 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/3

---

Non-opposition to a notified concentration

(Case M.7730 — Groupe Acticall/Sitel Worldwide Corporation)

(Text with EEA relevance)

(2015/C 306/05)

On 9 September 2015, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English language and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7730. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32015M7730. EUR-Lex is the online access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 17.9.2015 | EN | Official Journal of the European Union | C 306/4 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/4

---

Euro exchange rates (1)

16 September 2015

(2015/C 306/06)

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1228 |
| JPY | Japanese yen | 135,45 |
| DKK | Danish krone | 7,4610 |
| GBP | Pound sterling | 0,72665 |
| SEK | Swedish krona | 9,3251 |
| CHF | Swiss franc | 1,0943 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 9,2385 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,065 |
| HUF | Hungarian forint | 311,82 |
| PLN | Polish zloty | 4,1970 |
| RON | Romanian leu | 4,4265 |
| TRY | Turkish lira | 3,3706 |
| AUD | Australian dollar | 1,5677 |
| CAD | Canadian dollar | 1,4877 |
| HKD | Hong Kong dollar | 8,7021 |
| NZD | New Zealand dollar | 1,7701 |
| SGD | Singapore dollar | 1,5726 |
| KRW | South Korean won | 1 319,08 |
| ZAR | South African rand | 15,0000 |
| CNY | Chinese yuan renminbi | 7,1531 |
| HRK | Croatian kuna | 7,5740 |
| IDR | Indonesian rupiah | 16 204,00 |
| MYR | Malaysian ringgit | 4,7531 |
| PHP | Philippine peso | 52,356 |
| RUB | Russian rouble | 73,8232 |
| THB | Thai baht | 40,387 |
| BRL | Brazilian real | 4,3134 |
| MXN | Mexican peso | 18,6879 |
| INR | Indian rupee | 74,6213 |

Currency

Exchange rate

USD

US dollar

1,1228

JPY

Japanese yen

135,45

DKK

Danish krone

7,4610

GBP

Pound sterling

0,72665

SEK

Swedish krona

9,3251

CHF

Swiss franc

1,0943

ISK

Iceland króna

NOK

Norwegian krone

9,2385

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,065

HUF

Hungarian forint

311,82

PLN

Polish zloty

4,1970

RON

Romanian leu

4,4265

TRY

Turkish lira

3,3706

AUD

Australian dollar

1,5677

CAD

Canadian dollar

1,4877

HKD

Hong Kong dollar

8,7021

NZD

New Zealand dollar

1,7701

SGD

Singapore dollar

1,5726

KRW

South Korean won

1 319,08

ZAR

South African rand

15,0000

CNY

Chinese yuan renminbi

7,1531

HRK

Croatian kuna

7,5740

IDR

Indonesian rupiah

16 204,00

MYR

Malaysian ringgit

4,7531

PHP

Philippine peso

52,356

RUB

Russian rouble

73,8232

THB

Thai baht

40,387

BRL

Brazilian real

4,3134

MXN

Mexican peso

18,6879

INR

Indian rupee

74,6213

---

(1)  Source: reference exchange rate published by the ECB.

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/5 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/5

---

COMMISSION DECISION

of 10 February 2015

on the list of public holidays for 2016 for the institutions of the European Union

(2015/C 306/07)

PUBLIC HOLIDAYS FOR 2016

| 1 January | Friday, New Year’s Day |
| --- | --- |
| 24 March | Maundy Thursday |
| 25 March | Good Friday |
| 28 March | Easter Monday |
| 5 May | Thursday, Ascension Day |
| 6 May | Friday after Ascension Day |
| 9 May | Monday, Anniversary of the Declaration made by President Robert Schuman in 1950 |
| 16 May | Whit Monday |
| 21 July | Thursday, Belgian National Holiday |
| 15 August | Monday, Assumption Day |
| 1 November | Tuesday, All Saints’ Day |
| 2 November | Wednesday, All Souls’ Day |
| 26 December
  to
  30 December | Monday
  5 end-of-year days
  Friday |
| TOTAL | 17 days |

1 January

Friday, New Year’s Day

24 March

Maundy Thursday

25 March

Good Friday

28 March

Easter Monday

5 May

Thursday, Ascension Day

6 May

Friday after Ascension Day

9 May

Monday, Anniversary of the Declaration made by President Robert Schuman in 1950

16 May

Whit Monday

21 July

Thursday, Belgian National Holiday

15 August

Monday, Assumption Day

1 November

Tuesday, All Saints’ Day

2 November

Wednesday, All Souls’ Day

26 December

to

30 December

Monday

5 end-of-year days

Friday

TOTAL

17 days

Luxembourg: the above-mentioned dates also apply to Luxembourg, except that Thursday, 21 July is replaced by Thursday, 23 June, Luxembourg national holiday.

Work will resume as normal on Tuesday 3 January 2017.

Without prejudice to the final schedule of public holidays for 2017, Monday 2 January 2017 will be a holiday.

The Commission reserves the right to modify these provisions, should the needs of the service so require.

---

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

| 17.9.2015 | EN | Official Journal of the European Union | C 306/6 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/6

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2014

(2015/C 306/08)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2014, at their meeting on 12 December 2014:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/06/361 | Luminity | Iceland | 5.6.2014 |
| EU/1/06/367 | Diacomit | Liechtenstein | 28.2.2014 |
| EU/1/12/767 | Nimenrix | Liechtenstein | 30.6.2014 |
| EU/1/13/834 | Zoledronic Acid Accord | Iceland | 7.2.2014 |
| EU/1/13/834 | Zoledronic acid Accord | Liechtenstein | 28.2.2014 |
| EU/1/13/834 | Zoledronic acid Accord | Norway | 29.1.2014 |
| EU/1/13/837 | Tecfidera | Iceland | 11.2.2014 |
| EU/1/13/837 | Tecfidera | Liechtenstein | 28.2.2014 |
| EU/1/13/837 | Tecfidera | Norway | 5.2.2014 |
| EU/1/13/856 | Lonquex | Liechtenstein | 30.4.2014 |
| EU/1/13/875 | Deltyba | Iceland | 23.5.2014 |
| EU/1/13/875 | Deltyba | Liechtenstein | 30.6.2014 |
| EU/1/13/875 | Deltyba | Norway | 9.5.2014 |
| EU/1/13/887 | Fluenz Tetra | Iceland | 3.1.2014 |
| EU/1/13/887 | Fluenz Tetra | Liechtenstein | 28.2.2014 |
| EU/1/13/887 | Fluenz Tetra | Norway | 9.1.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Iceland | 15.1.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Liechtenstein | 28.2.2014 |
| EU/1/13/889 | Levetiracetam Hospira | Norway | 21.1.2014 |
| EU/1/13/890 | Cometriq | Iceland | 8.4.2014 |
| EU/1/13/890 | Cometriq | Liechtenstein | 30.4.2014 |
| EU/1/13/890 | Cometriq | Norway | 11.4.2014 |
| EU/1/13/891 | Brintellix | Iceland | 13.1.2014 |
| EU/1/13/891 | Brintellix | Liechtenstein | 28.2.2014 |
| EU/1/13/891 | Brintellix | Norway | 17.1.2014 |
| EU/1/13/892 | Tivicay | Iceland | 6.2.2014 |
| EU/1/13/892 | Tivicay | Liechtenstein | 28.2.2014 |
| EU/1/13/892 | Tivicay | Norway | 28.1.2014 |
| EU/1/13/893 | Opsumit | Iceland | 14.1.2014 |
| EU/1/13/893 | Opsumit | Norway | 17.1.2014 |
| EU/1/13/894 | Sovaldi | Iceland | 6.2.2014 |
| EU/1/13/894 | Sovaldi | Liechtenstein | 28.2.2014 |
| EU/1/13/894 | Sovaldi | Norway | 29.1.2014 |
| EU/1/13/895 | Cholic acid FGK | Iceland | 15.4.2014 |
| EU/1/13/895 | Cholic Acid FGK | Liechtenstein | 30.4.2014 |
| EU/1/13/895 | Kolsyre FGK | Norway | 28.4.2014 |
| EU/1/13/896 | Para-aminosalicylic acid Lucane | Iceland | 7.5.2014 |
| EU/1/13/896 | Para-aminosalicylic acid Lucane | Liechtenstein | 30.4.2014 |
| EU/1/13/896 | Granupas | Norway | 13.5.2014 |
| EU/1/13/898 | Anoro | Liechtenstein | 30.6.2014 |
| EU/1/13/899 | Laventair | Liechtenstein | 30.6.2014 |
| EU/1/13/900 | Xigduo | Iceland | 6.2.2014 |
| EU/1/13/900 | Xigduo | Liechtenstein | 28.2.2014 |
| EU/1/13/900 | Xigduo | Norway | 28.1.2014 |
| EU/1/13/901 | SIRTURO | Iceland | 4.4.2014 |
| EU/1/13/901 | Sirturo | Liechtenstein | 30.4.2014 |
| EU/1/13/901 | Sirturo | Norway | 14.3.2014 |
| EU/1/13/904 | Mirvaso | Iceland | 20.3.2014 |
| EU/1/13/904 | Mirvaso | Liechtenstein | 28.2.2014 |
| EU/1/13/904 | Mirvaso | Norway | 17.3.2014 |
| EU/1/13/905 | IZBA | Iceland | 18.3.2014 |
| EU/1/13/905 | Izba | Liechtenstein | 28.2.2014 |
| EU/1/13/905 | Izba | Norway | 17.3.2014 |
| EU/1/13/906 | Neuraceq | Iceland | 20.3.2014 |
| EU/1/13/906 | Neuraceq | Liechtenstein | 28.2.2014 |
| EU/1/13/906 | Neuraceq | Norway | 24.3.2014 |
| EU/1/13/907 | Adempas | Iceland | 8.4.2014 |
| EU/1/13/907 | Adempas | Liechtenstein | 30.4.2014 |
| EU/1/13/907 | Adempas | Norway | 7.4.2014 |
| EU/1/13/908 | Eperzan | Iceland | 9.4.2014 |
| EU/1/13/908 | Eperzan | Liechtenstein | 30.4.2014 |
| EU/1/13/908 | Eperzan | Norway | 15.4.2014 |
| EU/1/13/909 | Bemfola | Iceland | 14.4.2014 |
| EU/1/13/909 | Bemfola | Liechtenstein | 30.4.2014 |
| EU/1/13/909 | Bemfola | Norway | 25.4.2014 |
| EU/1/14/898 | ANORO | Iceland | 27.5.2014 |
| EU/1/14/898 | Anoro | Norway | 28.5.2014 |
| EU/1/14/899 | Laventair | Iceland | 27.5.2014 |
| EU/1/14/899 | Laventair | Norway | 4.6.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Iceland | 14.4.2014 |
| EU/1/14/911 | Rivastigmin 3M Health Care Ltd. | Liechtenstein | 30.4.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Norway | 14.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Iceland | 10.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Liechtenstein | 30.4.2014 |
| EU/1/14/912 | Zoledronic acid Teva Generics | Norway | 15.4.2014 |
| EU/1/14/913 | Latuda | Iceland | 8.4.2014 |
| EU/1/14/913 | Latuda | Liechtenstein | 30.4.2014 |
| EU/1/14/913 | Latuda | Norway | 8.4.2014 |
| EU/1/14/914 | Vimizim | Iceland | 23.5.2014 |
| EU/1/14/914 | Vimizim | Liechtenstein | 30.6.2014 |
| EU/1/14/914 | Vimizim | Norway | 23.5.2014 |
| EU/1/14/915 | Ebilfumin | Iceland | 5.6.2014 |
| EU/1/14/915 | Ebilfumin | Liechtenstein | 30.6.2014 |
| EU/1/14/915 | Ebilfumin | Norway | 18.6.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Iceland | 7.5.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Liechtenstein | 30.4.2014 |
| EU/1/14/916 | Pregabalin Pfizer | Norway | 13.5.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Liechtenstein | 30.6.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Norway | 21.5.2014 |
| EU/1/14/918 | Vokanamet | Iceland | 12.5.2014 |
| EU/1/14/918 | Vokanamet | Liechtenstein | 30.4.2014 |
| EU/1/14/918 | Vokanamet | Norway | 29.4.2014 |
| EU/1/14/919 | Hemangiol | Iceland | 12.5.2014 |
| EU/1/14/919 | Hemangiol | Liechtenstein | 30.4.2014 |
| EU/1/14/919 | Hemangiol | Norway | 8.5.2014 |
| EU/1/14/920 | DuoResp Spiromax | Iceland | 22.5.2014 |
| EU/1/14/920 | DuoResp Spiromax | Liechtenstein | 30.6.2014 |
| EU/1/14/920 | DuoResp Spiromax | Norway | 22.5.2014 |
| EU/1/14/921 | BiResp Spiromax | Iceland | 23.5.2014 |
| EU/1/14/921 | BiResp Spiromax | Liechtenstein | 30.6.2014 |
| EU/1/14/921 | BiResp Spiromax | Norway | 15.5.2014 |
| EU/1/14/922 | Incruse | Iceland | 22.5.2014 |
| EU/1/14/922 | Incruse | Liechtenstein | 30.6.2014 |
| EU/1/14/922 | Incruse | Norway | 22.5.2014 |
| EU/1/14/923 | Entyvio | Iceland | 5.6.2014 |
| EU/1/14/923 | Entyvio | Liechtenstein | 30.6.2014 |
| EU/1/14/923 | Entyvio | Norway | 17.6.2014 |
| EU/1/14/924 | OLYSIO | Iceland | 5.6.2014 |
| EU/1/14/924 | OLYSIO | Liechtenstein | 30.6.2014 |
| EU/1/14/924 | Olysio | Norway | 23.5.2014 |
| EU/1/14/928 | Sylvant | Iceland | 5.6.2014 |
| EU/1/14/928 | Sylvant | Liechtenstein | 30.6.2014 |
| EU/1/14/928 | Sylvant | Norway | 19.6.2014 |
| EU/1/14/929 | Revinty Ellipta | Iceland | 26.5.2014 |
| EU/1/14/929 | Revinty Ellipta | Liechtenstein | 30.6.2014 |
| EU/1/14/929 | Revinty Ellipta | Norway | 15.5.2014 |
| EU/1/14/930 | Jardiance | Iceland | 5.6.2014 |
| EU/1/14/930 | Jardiance | Liechtenstein | 30.6.2014 |
| EU/1/14/930 | Jardiance | Norway | 28.5.2014 |
| EU/2/09/096 | Leucogen | Liechtenstein | 30.6.2014 |
| EU/2/09/103 | Respiporc Flu3 | Norway | 13.2.2014 |
| EU/2/12/138 | RevitaCAM | Liechtenstein | 30.4.2014 |
| EU/2/12/140 | Poulvac E.coli | Norway | 7.4.2014 |
| EU/2/13/151 | Equilis West Nile | Norway | 7.4.2014 |
| EU/2/13/153 | Aftovaxpur Doe | Norway | 29.1.2014 |
| EU/2/13/154 | Apoquel | Norway | 21.1.2014 |
| EU/2/13/155 | Trifexis | Norway | 4.4.2014 |
| EU/2/13/156 | Vectra 3D | Norway | 4.4.2014 |
| EU/2/13/157 | Broadline | Norway | 24.3.2014 |
| EU/2/13/158 | Bravecto | Iceland | 28.2.2014 |
| EU/2/13/158 | Bravecto | Liechtenstein | 28.2.2014 |
| EU/2/13/158 | Bravecto | Norway | 21.3.2014 |
| EU/2/13/159 | NexGard | Iceland | 28.2.2014 |
| EU/2/13/159 | NexGard | Liechtenstein | 28.2.2014 |
| EU/2/13/159 | NexGard | Norway | 4.4.2014 |
| EU/2/13/160 | Fungitraxx | Iceland | 9.4.2014 |
| EU/2/13/160 | Fungitraxx | Liechtenstein | 30.4.2014 |
| EU/2/13/160 | Fungitraxx | Norway | 15.4.2014 |
| EU/2/14/161 | Equisolon | Iceland | 9.4.2014 |
| EU/2/14/161 | Equisolon | Liechtenstein | 30.4.2014 |
| EU/2/14/161 | Equisolon | Norway | 15.4.2014 |
| EU/2/14/162 | Parvoduk | Iceland | 9.5.2014 |
| EU/2/14/162 | Parvoduk | Norway | 6.6.2014 |
| EU/2/14/163 | Versican Plus DHPPi/L4R | Iceland | 6.6.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Iceland | 6.6.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Liechtenstein | 30.6.2014 |
| EU/2/14/165 | Vectra Felis | Iceland | 18.6.2014 |
| EU/2/14/165 | Vectra Felis | Liechtenstein | 30.6.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/06/361

Luminity

Iceland

5.6.2014

EU/1/06/367

Diacomit

Liechtenstein

28.2.2014

EU/1/12/767

Nimenrix

Liechtenstein

30.6.2014

EU/1/13/834

Zoledronic Acid Accord

Iceland

7.2.2014

EU/1/13/834

Zoledronic acid Accord

Liechtenstein

28.2.2014

EU/1/13/834

Zoledronic acid Accord

Norway

29.1.2014

EU/1/13/837

Tecfidera

Iceland

11.2.2014

EU/1/13/837

Tecfidera

Liechtenstein

28.2.2014

EU/1/13/837

Tecfidera

Norway

5.2.2014

EU/1/13/856

Lonquex

Liechtenstein

30.4.2014

EU/1/13/875

Deltyba

Iceland

23.5.2014

EU/1/13/875

Deltyba

Liechtenstein

30.6.2014

EU/1/13/875

Deltyba

Norway

9.5.2014

EU/1/13/887

Fluenz Tetra

Iceland

3.1.2014

EU/1/13/887

Fluenz Tetra

Liechtenstein

28.2.2014

EU/1/13/887

Fluenz Tetra

Norway

9.1.2014

EU/1/13/889

Levetiracetam Hospira

Iceland

15.1.2014

EU/1/13/889

Levetiracetam Hospira

Liechtenstein

28.2.2014

EU/1/13/889

Levetiracetam Hospira

Norway

21.1.2014

EU/1/13/890

Cometriq

Iceland

8.4.2014

EU/1/13/890

Cometriq

Liechtenstein

30.4.2014

EU/1/13/890

Cometriq

Norway

11.4.2014

EU/1/13/891

Brintellix

Iceland

13.1.2014

EU/1/13/891

Brintellix

Liechtenstein

28.2.2014

EU/1/13/891

Brintellix

Norway

17.1.2014

EU/1/13/892

Tivicay

Iceland

6.2.2014

EU/1/13/892

Tivicay

Liechtenstein

28.2.2014

EU/1/13/892

Tivicay

Norway

28.1.2014

EU/1/13/893

Opsumit

Iceland

14.1.2014

EU/1/13/893

Opsumit

Norway

17.1.2014

EU/1/13/894

Sovaldi

Iceland

6.2.2014

EU/1/13/894

Sovaldi

Liechtenstein

28.2.2014

EU/1/13/894

Sovaldi

Norway

29.1.2014

EU/1/13/895

Cholic acid FGK

Iceland

15.4.2014

EU/1/13/895

Cholic Acid FGK

Liechtenstein

30.4.2014

EU/1/13/895

Kolsyre FGK

Norway

28.4.2014

EU/1/13/896

Para-aminosalicylic acid Lucane

Iceland

7.5.2014

EU/1/13/896

Para-aminosalicylic acid Lucane

Liechtenstein

30.4.2014

EU/1/13/896

Granupas

Norway

13.5.2014

EU/1/13/898

Anoro

Liechtenstein

30.6.2014

EU/1/13/899

Laventair

Liechtenstein

30.6.2014

EU/1/13/900

Xigduo

Iceland

6.2.2014

EU/1/13/900

Xigduo

Liechtenstein

28.2.2014

EU/1/13/900

Xigduo

Norway

28.1.2014

EU/1/13/901

SIRTURO

Iceland

4.4.2014

EU/1/13/901

Sirturo

Liechtenstein

30.4.2014

EU/1/13/901

Sirturo

Norway

14.3.2014

EU/1/13/904

Mirvaso

Iceland

20.3.2014

EU/1/13/904

Mirvaso

Liechtenstein

28.2.2014

EU/1/13/904

Mirvaso

Norway

17.3.2014

EU/1/13/905

IZBA

Iceland

18.3.2014

EU/1/13/905

Izba

Liechtenstein

28.2.2014

EU/1/13/905

Izba

Norway

17.3.2014

EU/1/13/906

Neuraceq

Iceland

20.3.2014

EU/1/13/906

Neuraceq

Liechtenstein

28.2.2014

EU/1/13/906

Neuraceq

Norway

24.3.2014

EU/1/13/907

Adempas

Iceland

8.4.2014

EU/1/13/907

Adempas

Liechtenstein

30.4.2014

EU/1/13/907

Adempas

Norway

7.4.2014

EU/1/13/908

Eperzan

Iceland

9.4.2014

EU/1/13/908

Eperzan

Liechtenstein

30.4.2014

EU/1/13/908

Eperzan

Norway

15.4.2014

EU/1/13/909

Bemfola

Iceland

14.4.2014

EU/1/13/909

Bemfola

Liechtenstein

30.4.2014

EU/1/13/909

Bemfola

Norway

25.4.2014

EU/1/14/898

ANORO

Iceland

27.5.2014

EU/1/14/898

Anoro

Norway

28.5.2014

EU/1/14/899

Laventair

Iceland

27.5.2014

EU/1/14/899

Laventair

Norway

4.6.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Iceland

14.4.2014

EU/1/14/911

Rivastigmin 3M Health Care Ltd.

Liechtenstein

30.4.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Norway

14.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Iceland

10.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Liechtenstein

30.4.2014

EU/1/14/912

Zoledronic acid Teva Generics

Norway

15.4.2014

EU/1/14/913

Latuda

Iceland

8.4.2014

EU/1/14/913

Latuda

Liechtenstein

30.4.2014

EU/1/14/913

Latuda

Norway

8.4.2014

EU/1/14/914

Vimizim

Iceland

23.5.2014

EU/1/14/914

Vimizim

Liechtenstein

30.6.2014

EU/1/14/914

Vimizim

Norway

23.5.2014

EU/1/14/915

Ebilfumin

Iceland

5.6.2014

EU/1/14/915

Ebilfumin

Liechtenstein

30.6.2014

EU/1/14/915

Ebilfumin

Norway

18.6.2014

EU/1/14/916

Pregabalin Pfizer

Iceland

7.5.2014

EU/1/14/916

Pregabalin Pfizer

Liechtenstein

30.4.2014

EU/1/14/916

Pregabalin Pfizer

Norway

13.5.2014

EU/1/14/917

Ulunar Breezhaler

Liechtenstein

30.6.2014

EU/1/14/917

Ulunar Breezhaler

Norway

21.5.2014

EU/1/14/918

Vokanamet

Iceland

12.5.2014

EU/1/14/918

Vokanamet

Liechtenstein

30.4.2014

EU/1/14/918

Vokanamet

Norway

29.4.2014

EU/1/14/919

Hemangiol

Iceland

12.5.2014

EU/1/14/919

Hemangiol

Liechtenstein

30.4.2014

EU/1/14/919

Hemangiol

Norway

8.5.2014

EU/1/14/920

DuoResp Spiromax

Iceland

22.5.2014

EU/1/14/920

DuoResp Spiromax

Liechtenstein

30.6.2014

EU/1/14/920

DuoResp Spiromax

Norway

22.5.2014

EU/1/14/921

BiResp Spiromax

Iceland

23.5.2014

EU/1/14/921

BiResp Spiromax

Liechtenstein

30.6.2014

EU/1/14/921

BiResp Spiromax

Norway

15.5.2014

EU/1/14/922

Incruse

Iceland

22.5.2014

EU/1/14/922

Incruse

Liechtenstein

30.6.2014

EU/1/14/922

Incruse

Norway

22.5.2014

EU/1/14/923

Entyvio

Iceland

5.6.2014

EU/1/14/923

Entyvio

Liechtenstein

30.6.2014

EU/1/14/923

Entyvio

Norway

17.6.2014

EU/1/14/924

OLYSIO

Iceland

5.6.2014

EU/1/14/924

OLYSIO

Liechtenstein

30.6.2014

EU/1/14/924

Olysio

Norway

23.5.2014

EU/1/14/928

Sylvant

Iceland

5.6.2014

EU/1/14/928

Sylvant

Liechtenstein

30.6.2014

EU/1/14/928

Sylvant

Norway

19.6.2014

EU/1/14/929

Revinty Ellipta

Iceland

26.5.2014

EU/1/14/929

Revinty Ellipta

Liechtenstein

30.6.2014

EU/1/14/929

Revinty Ellipta

Norway

15.5.2014

EU/1/14/930

Jardiance

Iceland

5.6.2014

EU/1/14/930

Jardiance

Liechtenstein

30.6.2014

EU/1/14/930

Jardiance

Norway

28.5.2014

EU/2/09/096

Leucogen

Liechtenstein

30.6.2014

EU/2/09/103

Respiporc Flu3

Norway

13.2.2014

EU/2/12/138

RevitaCAM

Liechtenstein

30.4.2014

EU/2/12/140

Poulvac E.coli

Norway

7.4.2014

EU/2/13/151

Equilis West Nile

Norway

7.4.2014

EU/2/13/153

Aftovaxpur Doe

Norway

29.1.2014

EU/2/13/154

Apoquel

Norway

21.1.2014

EU/2/13/155

Trifexis

Norway

4.4.2014

EU/2/13/156

Vectra 3D

Norway

4.4.2014

EU/2/13/157

Broadline

Norway

24.3.2014

EU/2/13/158

Bravecto

Iceland

28.2.2014

EU/2/13/158

Bravecto

Liechtenstein

28.2.2014

EU/2/13/158

Bravecto

Norway

21.3.2014

EU/2/13/159

NexGard

Iceland

28.2.2014

EU/2/13/159

NexGard

Liechtenstein

28.2.2014

EU/2/13/159

NexGard

Norway

4.4.2014

EU/2/13/160

Fungitraxx

Iceland

9.4.2014

EU/2/13/160

Fungitraxx

Liechtenstein

30.4.2014

EU/2/13/160

Fungitraxx

Norway

15.4.2014

EU/2/14/161

Equisolon

Iceland

9.4.2014

EU/2/14/161

Equisolon

Liechtenstein

30.4.2014

EU/2/14/161

Equisolon

Norway

15.4.2014

EU/2/14/162

Parvoduk

Iceland

9.5.2014

EU/2/14/162

Parvoduk

Norway

6.6.2014

EU/2/14/163

Versican Plus DHPPi/L4R

Iceland

6.6.2014

EU/2/14/164

Versican Plus DHPPi/L4

Iceland

6.6.2014

EU/2/14/164

Versican Plus DHPPi/L4

Liechtenstein

30.6.2014

EU/2/14/165

Vectra Felis

Iceland

18.6.2014

EU/2/14/165

Vectra Felis

Liechtenstein

30.6.2014

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/03/265 | Bonviva | Iceland | 9.1.2014 |
| EU/1/03/265 | Bonviva | Norway | 16.1.2014 |
| EU/1/03/265 | Bonviva | Liechtenstein | 28.2.2014 |
| EU/1/03/271 | Advate | Iceland | 15.1.2014 |
| EU/1/03/271 | Advate | Norway | 17.1.2014 |
| EU/1/03/271 | Advate | Liechtenstein | 28.2.2014 |
| EU/1/04/274 | Velcade | Norway | 30.1.2014 |
| EU/1/04/274 | Velcade | Iceland | 5.2.2014 |
| EU/1/04/287 | Osseor | Norway | 18.6.2014 |
| EU/1/04/287 | Osseor | Liechtenstein | 30.6.2014 |
| EU/1/04/288 | Protelos | Norway | 18.6.2014 |
| EU/1/04/288 | Protelos | Liechtenstein | 30.6.2014 |
| EU/1/04/289 | Angiox | Liechtenstein | 30.6.2014 |
| EU/1/06/367 | Diacomit | Norway | 17.1.2014 |
| EU/1/06/367 | Diacomit | Iceland | 15.1.2014 |
| EU/1/07/423 | Vectibix | Liechtenstein | 28.2.2014 |
| EU/1/07/423 | Vectibix | Norway | 17.3.2014 |
| EU/1/07/423 | Vectibix | Iceland | 17.3.2014 |
| EU/1/07/436 | Isentress | Norway | 22.5.2014 |
| EU/1/07/436 | Isentress | Iceland | 26.5.2014 |
| EU/1/07/436 | Isentress | Liechtenstein | 30.6.2014 |
| EU/1/07/440 | Tyverb | Iceland | 19.3.2014 |
| EU/1/07/440 | Tyverb | Norway | 19.3.2014 |
| EU/1/07/440 | Tyverb | Liechtenstein | 30.4.2014 |
| EU/1/08/497 | Nplate | Iceland | 14.1.2014 |
| EU/1/08/497 | Nplate | Norway | 17.1.2014 |
| EU/1/08/497 | Nplate | Liechtenstein | 28.2.2014 |
| EU/1/08/501 | Ixiaro | Iceland | 18.3.2014 |
| EU/1/08/501 | Ixiaro | Norway | 25.3.2014 |
| EU/1/08/501 | Ixiaro | Liechtenstein | 30.4.2014 |
| EU/1/08/502 | Mepact | Iceland | 13.1.2014 |
| EU/1/08/502 | Mepact | Norway | 16.1.2014 |
| EU/1/08/502 | Mepact | Liechtenstein | 28.2.2014 |
| EU/1/09/508 | Synflorix | Liechtenstein | 28.2.2014 |
| EU/1/09/508 | Synflorix | Iceland | 18.3.2014 |
| EU/1/09/508 | Synflorix | Norway | 24.3.2014 |
| EU/1/09/509 | Ribavirin Teva | Norway | 29.1.2014 |
| EU/1/09/509 | Ribavirin Teva | Iceland | 6.2.2014 |
| EU/1/09/509 | Ribavirin Teva | Liechtenstein | 28.2.2014 |
| EU/1/09/510 | Fertavid | Liechtenstein | 28.2.2014 |
| EU/1/09/510 | Fertavid | Norway | 17.3.2014 |
| EU/1/09/510 | Fertavid | Iceland | 18.3.2014 |
| EU/1/09/511 | Conbriza | Norway | 17.3.2014 |
| EU/1/09/512 | Removab | Iceland | 10.1.2014 |
| EU/1/09/512 | Removab | Norway | 20.1.2014 |
| EU/1/09/512 | Removab | Liechtenstein | 28.2.2014 |
| EU/1/09/514 | Zebinix | Norway | 3.2.2014 |
| EU/1/09/514 | Zebinix | Iceland | 5.2.2014 |
| EU/1/09/514 | Zebinix | Liechtenstein | 28.2.2014 |
| EU/1/09/515 | CONTROLOC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/515 | CONTROLOC Control | Iceland | 18.3.2014 |
| EU/1/09/515 | Controloc Control | Norway | 20.3.2014 |
| EU/1/09/516 | SOMAC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/516 | SOMAC Control | Iceland | 18.3.2014 |
| EU/1/09/516 | Somac Control | Norway | 20.3.2014 |
| EU/1/09/517 | PANTOZOL Control | Liechtenstein | 28.2.2014 |
| EU/1/09/517 | PANTOZOL Control | Iceland | 18.3.2014 |
| EU/1/09/517 | Pantozol Control | Norway | 20.3.2014 |
| EU/1/09/518 | PANTECTA Control | Liechtenstein | 28.2.2014 |
| EU/1/09/518 | PANTECTA Control | Iceland | 18.3.2014 |
| EU/1/09/518 | Pantecta Control | Norway | 20.3.2014 |
| EU/1/09/519 | PANTOLOC Control | Liechtenstein | 28.2.2014 |
| EU/1/09/519 | PANTOLOC Control | Iceland | 18.3.2014 |
| EU/1/09/519 | Pantoloc Control | Norway | 20.3.2014 |
| EU/1/09/521 | Renvela | Iceland | 10.4.2014 |
| EU/1/09/521 | Renvela | Norway | 23.4.2014 |
| EU/1/09/521 | Renvela | Liechtenstein | 30.4.2014 |
| EU/1/09/522 | ellaOne | Iceland | 10.4.2014 |
| EU/1/09/522 | ellaOne | Norway | 25.4.2014 |
| EU/1/09/522 | ellaOne | Liechtenstein | 30.4.2014 |
| EU/1/09/523 | Modigraf | Liechtenstein | 28.2.2014 |
| EU/1/09/523 | Modigraf | Iceland | 12.3.2014 |
| EU/1/09/523 | Modigraf | Norway | 17.3.2014 |
| EU/1/09/524 | Qutenza | Liechtenstein | 30.4.2014 |
| EU/1/09/524 | Qutenza | Norway | 9.5.2014 |
| EU/1/09/524 | Qutenza | Iceland | 14.5.2014 |
| EU/1/09/525 | Nimvastid | Norway | 29.1.2014 |
| EU/1/09/525 | Nimvastid | Iceland | 5.2.2014 |
| EU/1/09/525 | Nimvastid | Liechtenstein | 28.2.2014 |
| EU/1/09/526 | Iressa | Iceland | 9.5.2014 |
| EU/1/09/526 | Iressa | Norway | 20.5.2014 |
| EU/1/09/526 | Iressa | Liechtenstein | 30.6.2014 |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Norway | 29.1.2014 |
| EU/1/09/527 | Ribavirin Teva Pharma B.V. | Iceland | 6.2.2014 |
| EU/1/09/528 | Peyona | Norway | 17.3.2014 |
| EU/1/09/528 | Peyona | Iceland | 19.3.2014 |
| EU/1/09/528 | Peyona | Liechtenstein | 30.4.2014 |
| EU/1/09/529 | Victoza | Norway | 25.4.2014 |
| EU/1/09/529 | Victoza | Liechtenstein | 30.4.2014 |
| EU/1/09/529 | Victoza | Iceland | 9.5.2014 |
| EU/1/09/530 | Repaglinide Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/531 | Instanyl | Norway | 29.4.2014 |
| EU/1/09/531 | Instanyl | Liechtenstein | 30.4.2014 |
| EU/1/09/531 | Instanyl | Iceland | 13.5.2014 |
| EU/1/09/532 | Clopidogrel Acino | Iceland | 10.4.2014 |
| EU/1/09/532 | Clopidogrel Acino | Norway | 11.4.2014 |
| EU/1/09/532 | Clopidogrel Acino | Liechtenstein | 30.4.2014 |
| EU/1/09/533 | Vedrop | Norway | 9.5.2014 |
| EU/1/09/533 | Vedrop | Iceland | 22.5.2014 |
| EU/1/09/535 | Grepid | Norway | 28.4.2014 |
| EU/1/09/535 | Grepid | Liechtenstein | 30.4.2014 |
| EU/1/09/535 | Grepid | Iceland | 9.5.2014 |
| EU/1/09/536 | Topotecan Actavis | Iceland | 20.6.2014 |
| EU/1/09/536 | Topotecan Actavis | Norway | 25.6.2014 |
| EU/1/09/536 | Topotecan Actavis | Liechtenstein | 30.6.2014 |
| EU/1/09/537 | Mozobil | Norway | 28.4.2014 |
| EU/1/09/537 | Mozobil | Liechtenstein | 30.4.2014 |
| EU/1/09/537 | Mozobil | Iceland | 9.5.2014 |
| EU/1/09/538 | Afinitor | Iceland | 6.6.2014 |
| EU/1/09/538 | Afinitor | Norway | 18.6.2014 |
| EU/1/09/539 | Samsca | Liechtenstein | 30.6.2014 |
| EU/1/09/540 | Clopidogrel Teva | Norway | 26.5.2014 |
| EU/1/09/540 | Clopidogrel Teva | Iceland | 6.6.2014 |
| EU/1/09/540 | Clopidogrel Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Norway | 3.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Iceland | 6.6.2014 |
| EU/1/09/541 | Clopidogrel ratiopharm GmbH | Liechtenstein | 30.6.2014 |
| EU/1/09/544 | Cimzia | Iceland | 6.6.2014 |
| EU/1/09/544 | Cimzia | Norway | 18.6.2014 |
| EU/1/09/544 | Cimzia | Liechtenstein | 30.6.2014 |
| EU/1/09/546 | Simponi | Liechtenstein | 30.6.2014 |
| EU/1/09/550 | Javlor | Norway | 18.6.2014 |
| EU/1/09/550 | Javlor | Liechtenstein | 30.6.2014 |
| EU/1/09/551 | Vizarsin | Norway | 26.5.2014 |
| EU/1/09/551 | Vizarsin | Iceland | 6.6.2014 |
| EU/1/09/551 | Vizarsin | Liechtenstein | 30.6.2014 |
| EU/1/09/552 | Topotecan Teva | Liechtenstein | 30.6.2014 |
| EU/1/09/553 | Zyllt | Iceland | 26.5.2014 |
| EU/1/09/553 | Zyllt | Norway | 26.5.2014 |
| EU/1/09/553 | Zyllt | Liechtenstein | 30.6.2014 |
| EU/1/09/555 | Clopidogrel TAD | Liechtenstein | 30.6.2014 |
| EU/1/09/556 | Clopidogrel Krka | Iceland | 26.5.2014 |
| EU/1/09/556 | Clopidogrel Krka | Norway | 26.5.2014 |
| EU/1/09/556 | Clopidogrel Krka | Liechtenstein | 30.6.2014 |
| EU/1/09/558 | Zylagren | Norway | 20.5.2014 |
| EU/1/09/558 | Zylagren | Iceland | 26.5.2014 |
| EU/1/09/558 | Zylagren | Liechtenstein | 30.6.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Iceland | 6.6.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Liechtenstein | 30.6.2014 |
| EU/1/09/560 | Clopidogrel dura | Iceland | 6.6.2014 |
| EU/1/09/560 | Clopidogrel DURA | Liechtenstein | 30.6.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Iceland | 26.5.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Norway | 26.5.2014 |
| EU/1/09/561 | Clopidogrel Teva Pharma | Liechtenstein | 30.6.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Liechtenstein | 30.6.2014 |
| EU/1/09/564 | Ilaris | Liechtenstein | 30.6.2014 |
| EU/1/09/571 | Pandemic Influenza Vaccine H5N1 Baxter | Iceland | 26.5.2014 |
| EU/1/09/571 | Pandemic influenza vaccine H5N1 Baxter | Norway | 26.5.2014 |
| EU/1/09/571 | Pandemic influenza vaccine H5N1 BAXTER | Liechtenstein | 30.6.2014 |
| EU/1/09/581 | Resolor | Iceland | 19.6.2014 |
| EU/1/09/581 | Resolor | Liechtenstein | 30.6.2014 |
| EU/1/10/625 | Arzerra | Norway | 28.1.2014 |
| EU/1/10/625 | Arzerra | Iceland | 12.2.2014 |
| EU/1/10/625 | Arzerra | Liechtenstein | 28.2.2014 |
| EU/1/11/699 | Fampyra | Iceland | 6.6.2014 |
| EU/1/11/699 | Fampyra | Norway | 18.6.2014 |
| EU/1/11/699 | Fampyra | Liechtenstein | 30.6.2014 |
| EU/1/11/749 | Caprelsa | Iceland | 15.1.2014 |
| EU/1/11/749 | Caprelsa | Norway | 20.1.2014 |
| EU/1/11/749 | Caprelsa | Liechtenstein | 28.2.2014 |
| EU/1/12/764 | Pixuvri | Iceland | 7.5.2014 |
| EU/1/12/764 | Pixuvri | Norway | 20.5.2014 |
| EU/1/12/764 | Pixuvri | Liechtenstein | 30.6.2014 |
| EU/1/13/818 | Bosulif | Liechtenstein | 28.2.2014 |
| EU/1/13/818 | Bosulif | Norway | 17.3.2014 |
| EU/1/13/818 | Bosulif | Iceland | 17.3.2014 |
| EU/1/99/103 | ReFacto AF | Iceland | 12.2.2014 |
| EU/1/99/110 | Sustiva | Liechtenstein | 30.4.2014 |
| EU/1/99/110 | Sustiva | Norway | 7.5.2014 |
| EU/1/99/110 | Sustiva | Iceland | 14.5.2014 |
| EU/1/99/111 | Stocrin | Liechtenstein | 30.4.2014 |
| EU/1/99/111 | Stocrin | Norway | 7.5.2014 |
| EU/1/99/111 | Stocrin | Iceland | 14.5.2014 |
| EU/1/99/112 | Ziagen | Iceland | 8.4.2014 |
| EU/1/99/112 | Ziagen | Norway | 15.4.2014 |
| EU/1/99/112 | Ziagen | Liechtenstein | 30.4.2014 |
| EU/1/99/114 | Zeffix | Liechtenstein | 30.6.2014 |
| EU/2/04/042 | Novem | Norway | 14.2.2014 |
| EU/2/04/043 | Equilis StrepE | Iceland | 7.5.2014 |
| EU/2/04/043 | Equilis StrepE | Liechtenstein | 30.6.2014 |
| EU/2/06/070 | Meloxidyl | Norway | 13.2.2014 |
| EU/2/07/071 | Slentrol | Norway | 13.2.2014 |
| EU/2/08/080 | Reconcile | Norway | 13.2.2014 |
| EU/2/08/084 | Trocoxil | Norway | 13.2.2014 |
| EU/2/08/085 | Easotic | Norway | 7.2.2014 |
| EU/2/08/088 | Acticam | Iceland | 6.1.2014 |
| EU/2/08/088 | Acticam | Norway | 29.1.2014 |
| EU/2/08/088 | Acticam | Liechtenstein | 28.2.2014 |
| EU/2/08/089 | Onsior | Norway | 17.3.2014 |
| EU/2/08/090 | Loxicom | Iceland | 19.3.2014 |
| EU/2/08/090 | Loxicom | Norway | 23.4.2014 |
| EU/2/08/090 | Loxicom | Liechtenstein | 30.4.2014 |
| EU/2/08/091 | Porcilis PCV | Iceland | 8.1.2014 |
| EU/2/08/091 | Porcilis PCV | Norway | 13.2.2014 |
| EU/2/08/092 | Startvac | Liechtenstein | 28.2.2014 |
| EU/2/08/092 | Startvac | Iceland | 28.2.2014 |
| EU/2/08/092 | Startvac | Norway | 23.4.2014 |
| EU/2/09/094 | BTVPUR AISap 8 | Iceland | 19.3.2014 |
| EU/2/09/094 | BTVPUR AlSap 8 | Liechtenstein | 30.4.2014 |
| EU/2/09/095 | Improvac | Liechtenstein | 30.4.2014 |
| EU/2/09/095 | Improvac | Iceland | 7.5.2014 |
| EU/2/09/096 | Leucogen | Iceland | 20.6.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Iceland | 19.6.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Liechtenstein | 30.6.2014 |
| EU/2/09/098 | Melovem | Iceland | 20.6.2014 |
| EU/2/09/098 | Melovem | Liechtenstein | 30.6.2014 |
| EU/2/09/099 | Suvaxyn PCV | Iceland | 19.6.2014 |
| EU/2/09/099 | Suvaxyn PCV | Liechtenstein | 30.6.2014 |
| EU/2/98/006 | Nobilis | Norway | 13.2.2014 |
| EU/2/99/014 | Stronghold | Norway | 19.2.2014 |
| EU/2/99/015 | Oxyglobin | Norway | 19.2.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/03/265

Bonviva

Iceland

9.1.2014

EU/1/03/265

Bonviva

Norway

16.1.2014

EU/1/03/265

Bonviva

Liechtenstein

28.2.2014

EU/1/03/271

Advate

Iceland

15.1.2014

EU/1/03/271

Advate

Norway

17.1.2014

EU/1/03/271

Advate

Liechtenstein

28.2.2014

EU/1/04/274

Velcade

Norway

30.1.2014

EU/1/04/274

Velcade

Iceland

5.2.2014

EU/1/04/287

Osseor

Norway

18.6.2014

EU/1/04/287

Osseor

Liechtenstein

30.6.2014

EU/1/04/288

Protelos

Norway

18.6.2014

EU/1/04/288

Protelos

Liechtenstein

30.6.2014

EU/1/04/289

Angiox

Liechtenstein

30.6.2014

EU/1/06/367

Diacomit

Norway

17.1.2014

EU/1/06/367

Diacomit

Iceland

15.1.2014

EU/1/07/423

Vectibix

Liechtenstein

28.2.2014

EU/1/07/423

Vectibix

Norway

17.3.2014

EU/1/07/423

Vectibix

Iceland

17.3.2014

EU/1/07/436

Isentress

Norway

22.5.2014

EU/1/07/436

Isentress

Iceland

26.5.2014

EU/1/07/436

Isentress

Liechtenstein

30.6.2014

EU/1/07/440

Tyverb

Iceland

19.3.2014

EU/1/07/440

Tyverb

Norway

19.3.2014

EU/1/07/440

Tyverb

Liechtenstein

30.4.2014

EU/1/08/497

Nplate

Iceland

14.1.2014

EU/1/08/497

Nplate

Norway

17.1.2014

EU/1/08/497

Nplate

Liechtenstein

28.2.2014

EU/1/08/501

Ixiaro

Iceland

18.3.2014

EU/1/08/501

Ixiaro

Norway

25.3.2014

EU/1/08/501

Ixiaro

Liechtenstein

30.4.2014

EU/1/08/502

Mepact

Iceland

13.1.2014

EU/1/08/502

Mepact

Norway

16.1.2014

EU/1/08/502

Mepact

Liechtenstein

28.2.2014

EU/1/09/508

Synflorix

Liechtenstein

28.2.2014

EU/1/09/508

Synflorix

Iceland

18.3.2014

EU/1/09/508

Synflorix

Norway

24.3.2014

EU/1/09/509

Ribavirin Teva

Norway

29.1.2014

EU/1/09/509

Ribavirin Teva

Iceland

6.2.2014

EU/1/09/509

Ribavirin Teva

Liechtenstein

28.2.2014

EU/1/09/510

Fertavid

Liechtenstein

28.2.2014

EU/1/09/510

Fertavid

Norway

17.3.2014

EU/1/09/510

Fertavid

Iceland

18.3.2014

EU/1/09/511

Conbriza

Norway

17.3.2014

EU/1/09/512

Removab

Iceland

10.1.2014

EU/1/09/512

Removab

Norway

20.1.2014

EU/1/09/512

Removab

Liechtenstein

28.2.2014

EU/1/09/514

Zebinix

Norway

3.2.2014

EU/1/09/514

Zebinix

Iceland

5.2.2014

EU/1/09/514

Zebinix

Liechtenstein

28.2.2014

EU/1/09/515

CONTROLOC Control

Liechtenstein

28.2.2014

EU/1/09/515

CONTROLOC Control

Iceland

18.3.2014

EU/1/09/515

Controloc Control

Norway

20.3.2014

EU/1/09/516

SOMAC Control

Liechtenstein

28.2.2014

EU/1/09/516

SOMAC Control

Iceland

18.3.2014

EU/1/09/516

Somac Control

Norway

20.3.2014

EU/1/09/517

PANTOZOL Control

Liechtenstein

28.2.2014

EU/1/09/517

PANTOZOL Control

Iceland

18.3.2014

EU/1/09/517

Pantozol Control

Norway

20.3.2014

EU/1/09/518

PANTECTA Control

Liechtenstein

28.2.2014

EU/1/09/518

PANTECTA Control

Iceland

18.3.2014

EU/1/09/518

Pantecta Control

Norway

20.3.2014

EU/1/09/519

PANTOLOC Control

Liechtenstein

28.2.2014

EU/1/09/519

PANTOLOC Control

Iceland

18.3.2014

EU/1/09/519

Pantoloc Control

Norway

20.3.2014

EU/1/09/521

Renvela

Iceland

10.4.2014

EU/1/09/521

Renvela

Norway

23.4.2014

EU/1/09/521

Renvela

Liechtenstein

30.4.2014

EU/1/09/522

ellaOne

Iceland

10.4.2014

EU/1/09/522

ellaOne

Norway

25.4.2014

EU/1/09/522

ellaOne

Liechtenstein

30.4.2014

EU/1/09/523

Modigraf

Liechtenstein

28.2.2014

EU/1/09/523

Modigraf

Iceland

12.3.2014

EU/1/09/523

Modigraf

Norway

17.3.2014

EU/1/09/524

Qutenza

Liechtenstein

30.4.2014

EU/1/09/524

Qutenza

Norway

9.5.2014

EU/1/09/524

Qutenza

Iceland

14.5.2014

EU/1/09/525

Nimvastid

Norway

29.1.2014

EU/1/09/525

Nimvastid

Iceland

5.2.2014

EU/1/09/525

Nimvastid

Liechtenstein

28.2.2014

EU/1/09/526

Iressa

Iceland

9.5.2014

EU/1/09/526

Iressa

Norway

20.5.2014

EU/1/09/526

Iressa

Liechtenstein

30.6.2014

EU/1/09/527

Ribavirin Teva Pharma BV

Norway

29.1.2014

EU/1/09/527

Ribavirin Teva Pharma B.V.

Iceland

6.2.2014

EU/1/09/528

Peyona

Norway

17.3.2014

EU/1/09/528

Peyona

Iceland

19.3.2014

EU/1/09/528

Peyona

Liechtenstein

30.4.2014

EU/1/09/529

Victoza

Norway

25.4.2014

EU/1/09/529

Victoza

Liechtenstein

30.4.2014

EU/1/09/529

Victoza

Iceland

9.5.2014

EU/1/09/530

Repaglinide Teva

Liechtenstein

30.6.2014

EU/1/09/531

Instanyl

Norway

29.4.2014

EU/1/09/531

Instanyl

Liechtenstein

30.4.2014

EU/1/09/531

Instanyl

Iceland

13.5.2014

EU/1/09/532

Clopidogrel Acino

Iceland

10.4.2014

EU/1/09/532

Clopidogrel Acino

Norway

11.4.2014

EU/1/09/532

Clopidogrel Acino

Liechtenstein

30.4.2014

EU/1/09/533

Vedrop

Norway

9.5.2014

EU/1/09/533

Vedrop

Iceland

22.5.2014

EU/1/09/535

Grepid

Norway

28.4.2014

EU/1/09/535

Grepid

Liechtenstein

30.4.2014

EU/1/09/535

Grepid

Iceland

9.5.2014

EU/1/09/536

Topotecan Actavis

Iceland

20.6.2014

EU/1/09/536

Topotecan Actavis

Norway

25.6.2014

EU/1/09/536

Topotecan Actavis

Liechtenstein

30.6.2014

EU/1/09/537

Mozobil

Norway

28.4.2014

EU/1/09/537

Mozobil

Liechtenstein

30.4.2014

EU/1/09/537

Mozobil

Iceland

9.5.2014

EU/1/09/538

Afinitor

Iceland

6.6.2014

EU/1/09/538

Afinitor

Norway

18.6.2014

EU/1/09/539

Samsca

Liechtenstein

30.6.2014

EU/1/09/540

Clopidogrel Teva

Norway

26.5.2014

EU/1/09/540

Clopidogrel Teva

Iceland

6.6.2014

EU/1/09/540

Clopidogrel Teva

Liechtenstein

30.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Norway

3.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Iceland

6.6.2014

EU/1/09/541

Clopidogrel ratiopharm GmbH

Liechtenstein

30.6.2014

EU/1/09/544

Cimzia

Iceland

6.6.2014

EU/1/09/544

Cimzia

Norway

18.6.2014

EU/1/09/544

Cimzia

Liechtenstein

30.6.2014

EU/1/09/546

Simponi

Liechtenstein

30.6.2014

EU/1/09/550

Javlor

Norway

18.6.2014

EU/1/09/550

Javlor

Liechtenstein

30.6.2014

EU/1/09/551

Vizarsin

Norway

26.5.2014

EU/1/09/551

Vizarsin

Iceland

6.6.2014

EU/1/09/551

Vizarsin

Liechtenstein

30.6.2014

EU/1/09/552

Topotecan Teva

Liechtenstein

30.6.2014

EU/1/09/553

Zyllt

Iceland

26.5.2014

EU/1/09/553

Zyllt

Norway

26.5.2014

EU/1/09/553

Zyllt

Liechtenstein

30.6.2014

EU/1/09/555

Clopidogrel TAD

Liechtenstein

30.6.2014

EU/1/09/556

Clopidogrel Krka

Iceland

26.5.2014

EU/1/09/556

Clopidogrel Krka

Norway

26.5.2014

EU/1/09/556

Clopidogrel Krka

Liechtenstein

30.6.2014

EU/1/09/558

Zylagren

Norway

20.5.2014

EU/1/09/558

Zylagren

Iceland

26.5.2014

EU/1/09/558

Zylagren

Liechtenstein

30.6.2014

EU/1/09/559

Clopidogrel Mylan

Iceland

6.6.2014

EU/1/09/559

Clopidogrel Mylan

Liechtenstein

30.6.2014

EU/1/09/560

Clopidogrel dura

Iceland

6.6.2014

EU/1/09/560

Clopidogrel DURA

Liechtenstein

30.6.2014

EU/1/09/561

Clopidogrel Teva Pharma

Iceland

26.5.2014

EU/1/09/561

Clopidogrel Teva Pharma

Norway

26.5.2014

EU/1/09/561

Clopidogrel Teva Pharma

Liechtenstein

30.6.2014

EU/1/09/562

Clopidogrel Krka d.d.

Liechtenstein

30.6.2014

EU/1/09/564

Ilaris

Liechtenstein

30.6.2014

EU/1/09/571

Pandemic Influenza Vaccine H5N1 Baxter

Iceland

26.5.2014

EU/1/09/571

Pandemic influenza vaccine H5N1 Baxter

Norway

26.5.2014

EU/1/09/571

Pandemic influenza vaccine H5N1 BAXTER

Liechtenstein

30.6.2014

EU/1/09/581

Resolor

Iceland

19.6.2014

EU/1/09/581

Resolor

Liechtenstein

30.6.2014

EU/1/10/625

Arzerra

Norway

28.1.2014

EU/1/10/625

Arzerra

Iceland

12.2.2014

EU/1/10/625

Arzerra

Liechtenstein

28.2.2014

EU/1/11/699

Fampyra

Iceland

6.6.2014

EU/1/11/699

Fampyra

Norway

18.6.2014

EU/1/11/699

Fampyra

Liechtenstein

30.6.2014

EU/1/11/749

Caprelsa

Iceland

15.1.2014

EU/1/11/749

Caprelsa

Norway

20.1.2014

EU/1/11/749

Caprelsa

Liechtenstein

28.2.2014

EU/1/12/764

Pixuvri

Iceland

7.5.2014

EU/1/12/764

Pixuvri

Norway

20.5.2014

EU/1/12/764

Pixuvri

Liechtenstein

30.6.2014

EU/1/13/818

Bosulif

Liechtenstein

28.2.2014

EU/1/13/818

Bosulif

Norway

17.3.2014

EU/1/13/818

Bosulif

Iceland

17.3.2014

EU/1/99/103

ReFacto AF

Iceland

12.2.2014

EU/1/99/110

Sustiva

Liechtenstein

30.4.2014

EU/1/99/110

Sustiva

Norway

7.5.2014

EU/1/99/110

Sustiva

Iceland

14.5.2014

EU/1/99/111

Stocrin

Liechtenstein

30.4.2014

EU/1/99/111

Stocrin

Norway

7.5.2014

EU/1/99/111

Stocrin

Iceland

14.5.2014

EU/1/99/112

Ziagen

Iceland

8.4.2014

EU/1/99/112

Ziagen

Norway

15.4.2014

EU/1/99/112

Ziagen

Liechtenstein

30.4.2014

EU/1/99/114

Zeffix

Liechtenstein

30.6.2014

EU/2/04/042

Novem

Norway

14.2.2014

EU/2/04/043

Equilis StrepE

Iceland

7.5.2014

EU/2/04/043

Equilis StrepE

Liechtenstein

30.6.2014

EU/2/06/070

Meloxidyl

Norway

13.2.2014

EU/2/07/071

Slentrol

Norway

13.2.2014

EU/2/08/080

Reconcile

Norway

13.2.2014

EU/2/08/084

Trocoxil

Norway

13.2.2014

EU/2/08/085

Easotic

Norway

7.2.2014

EU/2/08/088

Acticam

Iceland

6.1.2014

EU/2/08/088

Acticam

Norway

29.1.2014

EU/2/08/088

Acticam

Liechtenstein

28.2.2014

EU/2/08/089

Onsior

Norway

17.3.2014

EU/2/08/090

Loxicom

Iceland

19.3.2014

EU/2/08/090

Loxicom

Norway

23.4.2014

EU/2/08/090

Loxicom

Liechtenstein

30.4.2014

EU/2/08/091

Porcilis PCV

Iceland

8.1.2014

EU/2/08/091

Porcilis PCV

Norway

13.2.2014

EU/2/08/092

Startvac

Liechtenstein

28.2.2014

EU/2/08/092

Startvac

Iceland

28.2.2014

EU/2/08/092

Startvac

Norway

23.4.2014

EU/2/09/094

BTVPUR AISap 8

Iceland

19.3.2014

EU/2/09/094

BTVPUR AlSap 8

Liechtenstein

30.4.2014

EU/2/09/095

Improvac

Liechtenstein

30.4.2014

EU/2/09/095

Improvac

Iceland

7.5.2014

EU/2/09/096

Leucogen

Iceland

20.6.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Iceland

19.6.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Liechtenstein

30.6.2014

EU/2/09/098

Melovem

Iceland

20.6.2014

EU/2/09/098

Melovem

Liechtenstein

30.6.2014

EU/2/09/099

Suvaxyn PCV

Iceland

19.6.2014

EU/2/09/099

Suvaxyn PCV

Liechtenstein

30.6.2014

EU/2/98/006

Nobilis

Norway

13.2.2014

EU/2/99/014

Stronghold

Norway

19.2.2014

EU/2/99/015

Oxyglobin

Norway

19.2.2014

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/5/320 | Noxafil | Norway | 21.5.2014 |
| EU/1/5/320/002-003 | Noxafil | Iceland | 14.5.2014 |
| EU/1/08/492 | RoActemra | Norway | 19.5.2014 |
| EU/1/08/492/007 | RoActemra | Iceland | 22.5.2014 |
| EU/1/11/710/009-015 | Votubia | Iceland | 20.1.2014 |
| EU/1/13/825 | Imatinib Actavis | Norway | 23.6.2014 |
| EU/1/13/825/020-023 | Imatinib Actavis | Iceland | 27.6.2014 |
| EU/1/98/067 | MabThera | Norway | 11.4.2014 |
| EU/1/98/067/003 | MabThera | Iceland | 9.4.2014 |
| EU/2/04/044 | Aivlosin | Norway | 17.3.2014 |
| EU/2/09/098 | Melovem | Norway | 11.2.2014 |
| EU/2/10/115 | Comfortis | Norway | 29.1.2014 |
| EU/2/12/144 | Contacera | Norway | 21.3.2014 |
| EU/2/12/144/05-006 | Contacera | Iceland | 12.3.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/5/320

Noxafil

Norway

21.5.2014

EU/1/5/320/002-003

Noxafil

Iceland

14.5.2014

EU/1/08/492

RoActemra

Norway

19.5.2014

EU/1/08/492/007

RoActemra

Iceland

22.5.2014

EU/1/11/710/009-015

Votubia

Iceland

20.1.2014

EU/1/13/825

Imatinib Actavis

Norway

23.6.2014

EU/1/13/825/020-023

Imatinib Actavis

Iceland

27.6.2014

EU/1/98/067

MabThera

Norway

11.4.2014

EU/1/98/067/003

MabThera

Iceland

9.4.2014

EU/2/04/044

Aivlosin

Norway

17.3.2014

EU/2/09/098

Melovem

Norway

11.2.2014

EU/2/10/115

Comfortis

Norway

29.1.2014

EU/2/12/144

Contacera

Norway

21.3.2014

EU/2/12/144/05-006

Contacera

Iceland

12.3.2014

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/153 | Infanrix Penta | Iceland | 22.1.2014 |
| EU/1/06/339 | Preotact | Liechtenstein | 30.6.2014 |
| EU/1/06/349 | Avaglim | Iceland | 21.1.2014 |
| EU/1/06/381 | Daronrix | Iceland | 21.1.2014 |
| EU/1/09/554 | Clopidogrel ratiopharm | Iceland | 21.1.2014 |
| EU/1/09/554 | Clopidogrel ratiopharm | Norway | 11.2.2014 |
| EU/1/10/626 | Ribavirin BioPartners | Iceland | 24.1.2014 |
| EU/1/11/729 | Onduarp | Liechtenstein | 28.2.2014 |
| EU/1/11/729 | Onduarp | Iceland | 12.3.2014 |
| EU/1/11/729 | Onduarp | Norway | 27.3.2014 |
| EU/1/96/014 | Tritanrix HepB | Iceland | 7.2.2014 |
| EU/1/97/54 | Viracept | Iceland | 24.1.2014 |
| EU/2/00/022 | Ibaflin | Iceland | 21.1.2014 |
| EU/2/06/58 | Flexicam | Liechtenstein | 30.6.2014 |
| EU/2/06/58 | Flexicam | Norway | 3.6.2014 |
| EU/2/09/093 | Netvax | Norway | 7.1.2014 |

EU Number

Product

Country

Date of withdrawal

EU/1/00/153

Infanrix Penta

Iceland

22.1.2014

EU/1/06/339

Preotact

Liechtenstein

30.6.2014

EU/1/06/349

Avaglim

Iceland

21.1.2014

EU/1/06/381

Daronrix

Iceland

21.1.2014

EU/1/09/554

Clopidogrel ratiopharm

Iceland

21.1.2014

EU/1/09/554

Clopidogrel ratiopharm

Norway

11.2.2014

EU/1/10/626

Ribavirin BioPartners

Iceland

24.1.2014

EU/1/11/729

Onduarp

Liechtenstein

28.2.2014

EU/1/11/729

Onduarp

Iceland

12.3.2014

EU/1/11/729

Onduarp

Norway

27.3.2014

EU/1/96/014

Tritanrix HepB

Iceland

7.2.2014

EU/1/97/54

Viracept

Iceland

24.1.2014

EU/2/00/022

Ibaflin

Iceland

21.1.2014

EU/2/06/58

Flexicam

Liechtenstein

30.6.2014

EU/2/06/58

Flexicam

Norway

3.6.2014

EU/2/09/093

Netvax

Norway

7.1.2014

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2014:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/06/361 | Luminity | Liechtenstein | 28.2.2014 |
| EU/1/11/75 | Vibativ | Liechtenstein | 30.4.2014 |

EU-Number

Product

Country

Date of suspension

EU/1/06/361

Luminity

Liechtenstein

28.2.2014

EU/1/11/75

Vibativ

Liechtenstein

30.4.2014

---

| 17.9.2015 | EN | Official Journal of the European Union | C 306/24 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/24

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014

(2015/C 306/09)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July–31 December 2014, at their meeting on 20 March 2015:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Liechtenstein | 31.12.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Liechtenstein | 31.10.2014 |
| EU/1/09/591 | Multaq | Liechtenstein | 31.10.2014 |
| EU/1/09/595 | Sildenafil Actavis | Liechtenstein | 31.10.2014 |
| EU/1/09/598 | Nevirapine Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Liechtenstein | 31.8.2014 |
| EU/1/09/600 | Zutectra | Liechtenstein | 31.10.2014 |
| EU/1/11/688 | Cinryze | Liechtenstein | 31.12.2014 |
| EU/1/11/705 | Vibativ | Iceland | 27.10.2014 |
| EU/1/12/772 | Zoledronsäure Teva Pharma | Liechtenstein | 31.12.2014 |
| EU/1/13/902 | Translarna | Iceland | 15.8.2014 |
| EU/1/13/902 | Translarna | Liechtenstein | 31.8.2014 |
| EU/1/13/902 | Translarna | Norway | 12.8.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Iceland | 22.7.2014 |
| EU/1/14/931 | Mekinist | Iceland | 21.7.2014 |
| EU/1/14/931 | Mekinist | Liechtenstein | 31.8.2014 |
| EU/1/14/931 | Mekinist | Norway | 14.7.2014 |
| EU/1/14/933 | Simbrinza | Liechtenstein | 31.8.2014 |
| EU/1/14/933 | Simbrinza | Norway | 7.8.2014 |
| EU/1/14/933 | Simbrinza | Iceland | 14.8.2014 |
| EU/1/14/934 | Plegridy | Iceland | 15.8.2014 |
| EU/1/14/934 | Plegridy | Liechtenstein | 31.8.2014 |
| EU/1/14/934 | Plegridy | Norway | 13.8.2014 |
| EU/1/14/935 | Envarsus | Iceland | 14.8.2014 |
| EU/1/14/935 | Envarsus | Liechtenstein | 31.8.2014 |
| EU/1/14/935 | Envarsus | Norway | 13.8.2014 |
| EU/1/14/936 | Nuwiq | Iceland | 10.10.2014 |
| EU/1/14/936 | Nuwiq | Norway | 18.8.2014 |
| EU/1/14/937 | Gazyvaro | Iceland | 14.8.2014 |
| EU/1/14/937 | Gazyvaro | Liechtenstein | 31.8.2014 |
| EU/1/14/937 | Gazyvaro | Norway | 13.8.2014 |
| EU/1/14/938 | Zydelig | Iceland | 25.9.2014 |
| EU/1/14/938 | Zydelig | Liechtenstein | 31.10.2014 |
| EU/1/14/938 | Zydelig | Norway | 2.10.2014 |
| EU/1/14/939 | Daklinza | Iceland | 11.9.2014 |
| EU/1/14/939 | Daklinza | Liechtenstein | 31.8.2014 |
| EU/1/14/939 | Daklinza | Norway | 9.9.2014 |
| EU/1/14/940 | Triumeq | Iceland | 12.9.2014 |
| EU/1/14/940 | Triumeq | Liechtenstein | 31.10.2014 |
| EU/1/14/940 | Triumeq | Norway | 10.9.2014 |
| EU/1/14/941 | Vizamyl | Iceland | 11.9.2014 |
| EU/1/14/941 | Vizamyl | Liechtenstein | 31.8.2014 |
| EU/1/14/941 | Vizamyl | Norway | 12.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylic acid Teva | Iceland | 12.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylic acid Teva | Norway | 25.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylsäure Teva | Liechtenstein | 31.10.2014 |
| EU/1/14/943 | Velphoro | Iceland | 11.9.2014 |
| EU/1/14/943 | Velphoro | Liechtenstein | 31.8.2014 |
| EU/1/14/943 | Velphoro | Norway | 18.9.2014 |
| EU/1/14/944 | ABASRIA | Iceland | 24.9.2014 |
| EU/1/14/944 | ABASRIA | Liechtenstein | 31.10.2014 |
| EU/1/14/944 | ABASRIA | Norway | 24.9.2014 |
| EU/1/14/945 | IMBRUVICA | Iceland | 18.11.2014 |
| EU/1/14/945 | IMBRUVICA | Liechtenstein | 31.10.2014 |
| EU/1/14/945 | IMBRUVICA | Norway | 3.11.2014 |
| EU/1/14/946 | Accofil | Iceland | 26.9.2014 |
| EU/1/14/946 | Accofil | Liechtenstein | 31.10.2014 |
| EU/1/14/946 | Accofil | Norway | 14.10.2014 |
| EU/1/14/947 | Xultophy | Iceland | 25.9.2014 |
| EU/1/14/947 | Xultophy | Liechtenstein | 31.10.2014 |
| EU/1/14/947 | Xultophy | Norway | 25.9.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Iceland | 16.12.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Liechtenstein | 31.12.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Norway | 9.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Iceland | 12.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Liechtenstein | 31.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Norway | 9.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Iceland | 16.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Liechtenstein | 31.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Norway | 9.12.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Iceland | 25.9.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Liechtenstein | 31.10.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Norway | 2.10.2014 |
| EU/1/14/954 | Vargatef | Iceland | 20.12.2014 |
| EU/1/14/954 | Vargatef | Liechtenstein | 31.12.2014 |
| EU/1/14/954 | Vargatef | Norway | 1.12.2014 |
| EU/1/14/955 | Lymphoseek | Iceland | 19.12.2014 |
| EU/1/14/955 | Lymphoseek | Liechtenstein | 31.12.2014 |
| EU/1/14/955 | Lymphoseek | Norway | 10.12.2014 |
| EU/1/14/956 | Trulicity | Iceland | 20.12.2014 |
| EU/1/14/956 | Trulicity | Liechtenstein | 31.12.2014 |
| EU/1/14/956 | Trulicity | Norway | 1.12.2014 |
| EU/1/14/958 | Harvoni | Iceland | 9.12.2014 |
| EU/1/14/958 | Harvoni | Liechtenstein | 31.12.2014 |
| EU/1/14/958 | Harvoni | Norway | 3.12.2014 |
| EU/1/14/959 | Lynparza | Liechtenstein | 31.12.2014 |
| EU/1/14/960 | DUAVIVE | Liechtenstein | 31.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Iceland | 19.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Liechtenstein | 31.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Norway | 9.12.2014 |
| EU/1/14/962 | Moventig | Iceland | 20.12.2014 |
| EU/1/14/962 | Moventig | Liechtenstein | 31.12.2014 |
| EU/1/14/962 | Moventig | Norway | 12.12.2014 |
| EU/1/14/963 | Brimica Genuair | Iceland | 19.12.2014 |
| EU/1/14/963 | Brimica Genuair | Liechtenstein | 31.12.2014 |
| EU/1/14/963 | Brimica Genuair | Norway | 8.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Iceland | 19.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Liechtenstein | 31.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Norway | 8.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Norway | 8.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Iceland | 19.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Liechtenstein | 31.12.2014 |
| EU/1/14/967 | REZOLSTA | Iceland | 17.12.2014 |
| EU/1/14/967 | REZOLSTA | Liechtenstein | 31.12.2014 |
| EU/1/14/967 | REZOLSTA | Norway | 4.12.2014 |
| EU/1/14/969 | Scenesse | Liechtenstein | 31.12.2014 |
| EU/1/14/970 | Rixubis | Liechtenstein | 31.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Iceland | 5.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Liechtenstein | 31.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Norway | 19.12.2014 |
| EU/1/14/972 | Duloxetin Lilly | Liechtenstein | 31.12.2014 |
| EU/1/14/972 | Duloxetine Lilly | Norway | 17.12.2014 |
| EU/2/09/101 | Zolvix | Liechtenstein | 31.12.2014 |
| EU/2/13/150 | Oncept IL-2 | Norway | 26.9.2014 |
| EU/2/14/163 | Versican Plus DHPPi/L4R | Norway | 10.7.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Norway | 21.7.2014 |
| EU/2/14/165 | Vectra Felis | Norway | 10.7.2014 |
| EU/2/14/166 | ERYSENG | Iceland | 21.7.2014 |
| EU/2/14/166 | Eryseng | Norway | 5.8.2014 |
| EU/2/14/166 | ERYSENG | Liechtenstein | 31.8.2014 |
| EU/2/14/167 | ERYSENG PARVO | Iceland | 12.8.2014 |
| EU/2/14/167 | Eryseng Parvo | Norway | 5.8.2014 |
| EU/2/14/167 | ERYSENG PARVO | Liechtenstein | 31.8.2014 |
| EU/2/14/168 | Versican Plus Pi | Iceland | 21.7.2014 |
| EU/2/14/168 | Versican Plus Pi | Liechtenstein | 31.8.2014 |
| EU/2/14/168 | Versican Plus Pi | Norway | 5.8.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Iceland | 21.7.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Liechtenstein | 31.8.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Norway | 5.8.2014 |
| EU/2/14/170 | OSURNIA | Iceland | 2.9.2014 |
| EU/2/14/170 | Osurnia | Liechtenstein | 31.8.2014 |
| EU/2/14/170 | Osurnia | Norway | 22.9.2014 |
| EU/2/14/171 | Versican Plus L4 | Iceland | 2.9.2014 |
| EU/2/14/171 | Versican Plus L4 | Liechtenstein | 31.8.2014 |
| EU/2/14/171 | Versican Plus L4 | Norway | 11.11.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Iceland | 2.9.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Liechtenstein | 31.8.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Norway | 11.11.2014 |
| EU/2/14/173 | Versican Plus Pi/L4R | Norway | 11.11.2014 |
| EU/2/14/173 | Versican Plus Pi/L4R | Iceland | 31.7.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Iceland | 24.9.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Liechtenstein | 31.10.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Norway | 11.11.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Norway | 15.12.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Iceland | 4.12.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Liechtenstein | 31.12.2014 |
| EU/2/14/176 | Bovela | Liechtenstein | 31.12.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/09/527

Ribavirin Teva Pharma BV

Liechtenstein

31.12.2014

EU/1/09/585

Rivastigmine 1A Pharma

Liechtenstein

31.10.2014

EU/1/09/591

Multaq

Liechtenstein

31.10.2014

EU/1/09/595

Sildenafil Actavis

Liechtenstein

31.10.2014

EU/1/09/598

Nevirapine Teva

Liechtenstein

31.8.2014

EU/1/09/599

Rivastigmine Sandoz

Liechtenstein

31.8.2014

EU/1/09/600

Zutectra

Liechtenstein

31.10.2014

EU/1/11/688

Cinryze

Liechtenstein

31.12.2014

EU/1/11/705

Vibativ

Iceland

27.10.2014

EU/1/12/772

Zoledronsäure Teva Pharma

Liechtenstein

31.12.2014

EU/1/13/902

Translarna

Iceland

15.8.2014

EU/1/13/902

Translarna

Liechtenstein

31.8.2014

EU/1/13/902

Translarna

Norway

12.8.2014

EU/1/14/917

Ulunar Breezhaler

Iceland

22.7.2014

EU/1/14/931

Mekinist

Iceland

21.7.2014

EU/1/14/931

Mekinist

Liechtenstein

31.8.2014

EU/1/14/931

Mekinist

Norway

14.7.2014

EU/1/14/933

Simbrinza

Liechtenstein

31.8.2014

EU/1/14/933

Simbrinza

Norway

7.8.2014

EU/1/14/933

Simbrinza

Iceland

14.8.2014

EU/1/14/934

Plegridy

Iceland

15.8.2014

EU/1/14/934

Plegridy

Liechtenstein

31.8.2014

EU/1/14/934

Plegridy

Norway

13.8.2014

EU/1/14/935

Envarsus

Iceland

14.8.2014

EU/1/14/935

Envarsus

Liechtenstein

31.8.2014

EU/1/14/935

Envarsus

Norway

13.8.2014

EU/1/14/936

Nuwiq

Iceland

10.10.2014

EU/1/14/936

Nuwiq

Norway

18.8.2014

EU/1/14/937

Gazyvaro

Iceland

14.8.2014

EU/1/14/937

Gazyvaro

Liechtenstein

31.8.2014

EU/1/14/937

Gazyvaro

Norway

13.8.2014

EU/1/14/938

Zydelig

Iceland

25.9.2014

EU/1/14/938

Zydelig

Liechtenstein

31.10.2014

EU/1/14/938

Zydelig

Norway

2.10.2014

EU/1/14/939

Daklinza

Iceland

11.9.2014

EU/1/14/939

Daklinza

Liechtenstein

31.8.2014

EU/1/14/939

Daklinza

Norway

9.9.2014

EU/1/14/940

Triumeq

Iceland

12.9.2014

EU/1/14/940

Triumeq

Liechtenstein

31.10.2014

EU/1/14/940

Triumeq

Norway

10.9.2014

EU/1/14/941

Vizamyl

Iceland

11.9.2014

EU/1/14/941

Vizamyl

Liechtenstein

31.8.2014

EU/1/14/941

Vizamyl

Norway

12.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylic acid Teva

Iceland

12.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylic acid Teva

Norway

25.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylsäure Teva

Liechtenstein

31.10.2014

EU/1/14/943

Velphoro

Iceland

11.9.2014

EU/1/14/943

Velphoro

Liechtenstein

31.8.2014

EU/1/14/943

Velphoro

Norway

18.9.2014

EU/1/14/944

ABASRIA

Iceland

24.9.2014

EU/1/14/944

ABASRIA

Liechtenstein

31.10.2014

EU/1/14/944

ABASRIA

Norway

24.9.2014

EU/1/14/945

IMBRUVICA

Iceland

18.11.2014

EU/1/14/945

IMBRUVICA

Liechtenstein

31.10.2014

EU/1/14/945

IMBRUVICA

Norway

3.11.2014

EU/1/14/946

Accofil

Iceland

26.9.2014

EU/1/14/946

Accofil

Liechtenstein

31.10.2014

EU/1/14/946

Accofil

Norway

14.10.2014

EU/1/14/947

Xultophy

Iceland

25.9.2014

EU/1/14/947

Xultophy

Liechtenstein

31.10.2014

EU/1/14/947

Xultophy

Norway

25.9.2014

EU/1/14/948

Budesonide/Formoterol Teva

Iceland

16.12.2014

EU/1/14/948

Budesonide/Formoterol Teva

Liechtenstein

31.12.2014

EU/1/14/948

Budesonide/Formoterol Teva

Norway

9.12.2014

EU/1/14/949

Vylaer Spiromax

Iceland

12.12.2014

EU/1/14/949

Vylaer Spiromax

Liechtenstein

31.12.2014

EU/1/14/949

Vylaer Spiromax

Norway

9.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Iceland

16.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Liechtenstein

31.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Norway

9.12.2014

EU/1/14/951

Busulfan Fresenius Kabi

Iceland

25.9.2014

EU/1/14/951

Busulfan Fresenius Kabi

Liechtenstein

31.10.2014

EU/1/14/951

Busulfan Fresenius Kabi

Norway

2.10.2014

EU/1/14/954

Vargatef

Iceland

20.12.2014

EU/1/14/954

Vargatef

Liechtenstein

31.12.2014

EU/1/14/954

Vargatef

Norway

1.12.2014

EU/1/14/955

Lymphoseek

Iceland

19.12.2014

EU/1/14/955

Lymphoseek

Liechtenstein

31.12.2014

EU/1/14/955

Lymphoseek

Norway

10.12.2014

EU/1/14/956

Trulicity

Iceland

20.12.2014

EU/1/14/956

Trulicity

Liechtenstein

31.12.2014

EU/1/14/956

Trulicity

Norway

1.12.2014

EU/1/14/958

Harvoni

Iceland

9.12.2014

EU/1/14/958

Harvoni

Liechtenstein

31.12.2014

EU/1/14/958

Harvoni

Norway

3.12.2014

EU/1/14/959

Lynparza

Liechtenstein

31.12.2014

EU/1/14/960

DUAVIVE

Liechtenstein

31.12.2014

EU/1/14/961

Tadalafil Mylan

Iceland

19.12.2014

EU/1/14/961

Tadalafil Mylan

Liechtenstein

31.12.2014

EU/1/14/961

Tadalafil Mylan

Norway

9.12.2014

EU/1/14/962

Moventig

Iceland

20.12.2014

EU/1/14/962

Moventig

Liechtenstein

31.12.2014

EU/1/14/962

Moventig

Norway

12.12.2014

EU/1/14/963

Brimica Genuair

Iceland

19.12.2014

EU/1/14/963

Brimica Genuair

Liechtenstein

31.12.2014

EU/1/14/963

Brimica Genuair

Norway

8.12.2014

EU/1/14/964

Duaklir Genuair

Iceland

19.12.2014

EU/1/14/964

Duaklir Genuair

Liechtenstein

31.12.2014

EU/1/14/964

Duaklir Genuair

Norway

8.12.2014

EU/1/14/965

Ketoconazole HRA

Norway

8.12.2014

EU/1/14/965

Ketoconazole HRA

Iceland

19.12.2014

EU/1/14/965

Ketoconazole HRA

Liechtenstein

31.12.2014

EU/1/14/967

REZOLSTA

Iceland

17.12.2014

EU/1/14/967

REZOLSTA

Liechtenstein

31.12.2014

EU/1/14/967

REZOLSTA

Norway

4.12.2014

EU/1/14/969

Scenesse

Liechtenstein

31.12.2014

EU/1/14/970

Rixubis

Liechtenstein

31.12.2014

EU/1/14/971

Paliperidone Janssen

Iceland

5.12.2014

EU/1/14/971

Paliperidone Janssen

Liechtenstein

31.12.2014

EU/1/14/971

Paliperidone Janssen

Norway

19.12.2014

EU/1/14/972

Duloxetin Lilly

Liechtenstein

31.12.2014

EU/1/14/972

Duloxetine Lilly

Norway

17.12.2014

EU/2/09/101

Zolvix

Liechtenstein

31.12.2014

EU/2/13/150

Oncept IL-2

Norway

26.9.2014

EU/2/14/163

Versican Plus DHPPi/L4R

Norway

10.7.2014

EU/2/14/164

Versican Plus DHPPi/L4

Norway

21.7.2014

EU/2/14/165

Vectra Felis

Norway

10.7.2014

EU/2/14/166

ERYSENG

Iceland

21.7.2014

EU/2/14/166

Eryseng

Norway

5.8.2014

EU/2/14/166

ERYSENG

Liechtenstein

31.8.2014

EU/2/14/167

ERYSENG PARVO

Iceland

12.8.2014

EU/2/14/167

Eryseng Parvo

Norway

5.8.2014

EU/2/14/167

ERYSENG PARVO

Liechtenstein

31.8.2014

EU/2/14/168

Versican Plus Pi

Iceland

21.7.2014

EU/2/14/168

Versican Plus Pi

Liechtenstein

31.8.2014

EU/2/14/168

Versican Plus Pi

Norway

5.8.2014

EU/2/14/169

Versican Plus DHPPi

Iceland

21.7.2014

EU/2/14/169

Versican Plus DHPPi

Liechtenstein

31.8.2014

EU/2/14/169

Versican Plus DHPPi

Norway

5.8.2014

EU/2/14/170

OSURNIA

Iceland

2.9.2014

EU/2/14/170

Osurnia

Liechtenstein

31.8.2014

EU/2/14/170

Osurnia

Norway

22.9.2014

EU/2/14/171

Versican Plus L4

Iceland

2.9.2014

EU/2/14/171

Versican Plus L4

Liechtenstein

31.8.2014

EU/2/14/171

Versican Plus L4

Norway

11.11.2014

EU/2/14/172

Versican Plus Pi/L4

Iceland

2.9.2014

EU/2/14/172

Versican Plus Pi/L4

Liechtenstein

31.8.2014

EU/2/14/172

Versican Plus Pi/L4

Norway

11.11.2014

EU/2/14/173

Versican Plus Pi/L4R

Norway

11.11.2014

EU/2/14/173

Versican Plus Pi/L4R

Iceland

31.7.2014

EU/2/14/174

Nobilis IB Primo QX

Iceland

24.9.2014

EU/2/14/174

Nobilis IB Primo QX

Liechtenstein

31.10.2014

EU/2/14/174

Nobilis IB Primo QX

Norway

11.11.2014

EU/2/14/175

Porcilis PCV M Hyo

Norway

15.12.2014

EU/2/14/175

Porcilis PCV M Hyo

Iceland

4.12.2014

EU/2/14/175

Porcilis PCV M Hyo

Liechtenstein

31.12.2014

EU/2/14/176

Bovela

Liechtenstein

31.12.2014

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/04/287 | Osseor | Iceland | 16.9.2014 |
| EU/1/04/288 | Protelos | Iceland | 16.9.2014 |
| EU/1/04/289 | Angiox | Iceland | 18.7.2014 |
| EU/1/04/289 | Angiox | Norway | 8.7.2014 |
| EU/1/04/295 | Xagrid | Liechtenstein | 31.8.2014 |
| EU/1/04/295 | Xagrid | Iceland | 14.8.2014 |
| EU/1/04/295 | Xagrid | Norway | 7.8.2014 |
| EU/1/04/298 | Kivexa | Liechtenstein | 31.12.2014 |
| EU/1/04/298 | Kivexa | Iceland | 10.12.2014 |
| EU/1/04/298 | Kivexa | Norway | 17.12.2014 |
| EU/1/04/299 | Fendrix | Liechtenstein | 31.12.2014 |
| EU/1/04/299 | Fendrix | Iceland | 9.12.2014 |
| EU/1/04/299 | Fendrix | Norway | 4.12.2014 |
| EU/1/04/300 | Avastin | Liechtenstein | 31.12.2014 |
| EU/1/04/300 | Avastin | Iceland | 12.12.2014 |
| EU/1/04/300 | Avastin | Norway | 28.11.2014 |
| EU/1/04/302 | Prialt | Liechtenstein | 31.10.2014 |
| EU/1/04/302 | Prialt | Iceland | 24.9.2014 |
| EU/1/04/302 | Prialt | Norway | 26.9.2014 |
| EU/1/09/511 | Conbriza | Iceland | 16.9.2014 |
| EU/1/09/530 | Repaglinide Teva | Iceland | 16.7.2014 |
| EU/1/09/530 | Repaglinide Teva | Norway | 1.7.2014 |
| EU/1/09/539 | Samsca | Iceland | 18.7.2014 |
| EU/1/09/539 | Samsca | Norway | 1.7.2014 |
| EU/1/09/545 | Onglyza | Liechtenstein | 31.8.2014 |
| EU/1/09/545 | Onglyza | Iceland | 14.8.2014 |
| EU/1/09/545 | Onglyza | Norway | 25.8.2014 |
| EU/1/09/546 | Simponi | Iceland | 18.7.2014 |
| EU/1/09/546 | Simponi | Norway | 10.7.2014 |
| EU/1/09/550 | Javlor | Iceland | 22.7.2014 |
| EU/1/09/552 | Topotecan Teva | Iceland | 18.7.2014 |
| EU/1/09/552 | Topotecan Teva | Norway | 10.7.2014 |
| EU/1/09/555 | Clopidogrel TAD | Iceland | 22.7.2014 |
| EU/1/09/555 | Clopidogrel TAD | Norway | 1.7.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Norway | 1.7.2014 |
| EU/1/09/560 | Clopidogrel DURA | Norway | 1.7.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Iceland | 22.7.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Norway | 1.7.2014 |
| EU/1/09/563 | ChondroCelect | Liechtenstein | 31.8.2014 |
| EU/1/09/563 | ChondroCelect | Iceland | 9.9.2014 |
| EU/1/09/563 | ChondroCelect | Norway | 10.9.2014 |
| EU/1/09/564 | Ilaris | Iceland | 18.7.2014 |
| EU/1/09/564 | Ilaris | Norway | 10.7.2014 |
| EU/1/09/565 | Biopoin | Liechtenstein | 31.10.2014 |
| EU/1/09/565 | Biopoin | Iceland | 10.9.2014 |
| EU/1/09/565 | Biopoin | Norway | 8.9.2014 |
| EU/1/09/566 | Lamivudine Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/566 | Lamivudine Teva | Iceland | 23.9.2014 |
| EU/1/09/566 | Lamivudine Teva | Norway | 9.10.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Liechtenstein | 31.10.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Iceland | 25.9.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Norway | 29.9.2014 |
| EU/1/09/569 | Exforge HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/569 | Exforge HCT | Iceland | 18.7.2014 |
| EU/1/09/569 | Exforge HCT | Norway | 29.7.2014 |
| EU/1/09/572 | Vantavo | Liechtenstein | 31.10.2014 |
| EU/1/09/572 | Vantavo | Iceland | 25.9.2014 |
| EU/1/09/572 | Vantavo | Norway | 26.9.2014 |
| EU/1/09/573 | Eporatio | Liechtenstein | 31.10.2014 |
| EU/1/09/573 | Eporatio | Iceland | 24.9.2014 |
| EU/1/09/573 | Eporatio | Norway | 29.9.2014 |
| EU/1/09/574 | Dafiro HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/574 | Dafiro HCT | Iceland | 22.7.2014 |
| EU/1/09/574 | Dafiro HCT | Norway | 4.8.2014 |
| EU/1/09/575 | Copalia HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/575 | Copalia HCT | Iceland | 22.7.2014 |
| EU/1/09/575 | Copalia HCT | Norway | 4.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Iceland | 13.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Norway | 4.8.2014 |
| EU/1/09/577 | Foclivia | Liechtenstein | 31.8.2014 |
| EU/1/09/577 | Foclivia | Iceland | 21.7.2014 |
| EU/1/09/577 | Foclivia | Norway | 29.7.2014 |
| EU/1/09/578 | Adjupanrix | Liechtenstein | 31.8.2014 |
| EU/1/09/578 | Adjupanrix | Iceland | 14.8.2014 |
| EU/1/09/578 | Adjupanrix | Norway | 13.8.2014 |
| EU/1/09/579 | Repaglinide Krka | Liechtenstein | 31.10.2014 |
| EU/1/09/579 | Repaglinide Krka | Iceland | 10.9.2014 |
| EU/1/09/579 | Repaglinide Krka | Norway | 9.9.2014 |
| EU/1/09/580 | Enyglid | Liechtenstein | 31.8.2014 |
| EU/1/09/580 | Enyglid | Iceland | 9.9.2014 |
| EU/1/09/580 | Enyglid | Norway | 10.9.2014 |
| EU/1/09/581 | Resolor | Norway | 1.7.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorothiazid | Liechtenstein | 31.12.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorothiazide Teva | Iceland | 9.12.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorotiazide Teva | Norway | 27.11.2014 |
| EU/1/09/584 | Sildenafil Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/584 | Sildenafil Teva | Iceland | 23.9.2014 |
| EU/1/09/584 | Sildenafil Teva | Norway | 2.10.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Iceland | 9.9.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Norway | 10.9.2014 |
| EU/1/09/586 | Oslif Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/586 | Oslif Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/586 | Oslif Breezhaler | Norway | 14.10.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Liechtenstein | 31.8.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Iceland | 9.9.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Norway | 10.9.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Liechtenstein | 31.8.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Iceland | 9.9.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Norway | 10.9.2014 |
| EU/1/09/589 | Rivastigmine HEXAL | Liechtenstein | 31.8.2014 |
| EU/1/09/589 | Rivastigmine HEXAL | Iceland | 13.8.2014 |
| EU/1/09/589 | Rivastigmine Hexal | Norway | 13.8.2014 |
| EU/1/09/590 | Prevenar 13 | Liechtenstein | 31.12.2014 |
| EU/1/09/590 | Prevenar 13 | Iceland | 10.10.2014 |
| EU/1/09/590 | Prevenar 13 | Norway | 15.10.2014 |
| EU/1/09/591 | Multaq | Norway | 29.9.2014 |
| EU/1/09/591 | Multaq | Iceland | 26.9.2014 |
| EU/1/09/592 | Olazax Disperzi | Liechtenstein | 31.8.2014 |
| EU/1/09/592 | Olazax Disperzi | Iceland | 4.9.2014 |
| EU/1/09/592 | Olazax Disperzi | Norway | 27.8.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Norway | 14.10.2014 |
| EU/1/09/594 | Hirobrez Breezhaler | Norway | 14.10.2014 |
| EU/1/09/594 | Hirobriz Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/594 | Hirobriz Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/595 | Sildenafil Actavis | Iceland | 23.9.2014 |
| EU/1/09/595 | Sildenafil Actavis | Norway | 1.10.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Liechtenstein | 31.10.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Iceland | 23.9.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Norway | 9.10.2014 |
| EU/1/09/597 | Olazax | Iceland | 9.9.2014 |
| EU/1/09/597 | Olazax | Norway | 10.9.2014 |
| EU/1/09/598 | Nevirapine Teva | Iceland | 10.9.2014 |
| EU/1/09/598 | Nevirapine Teva | Norway | 9.9.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Iceland | 13.8.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Norway | 13.8.2014 |
| EU/1/09/600 | Zutectra | Iceland | 24.9.2014 |
| EU/1/09/600 | Zutectra | Norway | 15.10.2014 |
| EU/1/09/601 | Firdapse | Norway | 18.12.2014 |
| EU/1/09/602 | Scintimun | Liechtenstein | 31.8.2014 |
| EU/1/09/602 | Scintimun | Iceland | 10.9.2014 |
| EU/1/09/602 | Scintimun | Norway | 18.9.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Liechtenstein | 31.10.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Iceland | 23.9.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Norway | 2.10.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Liechtenstein | 31.12.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Iceland | 12.12.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Norway | 28.11.2014 |
| EU/1/09/605 | Temomedac | Liechtenstein | 31.8.2014 |
| EU/1/09/605 | Temomedac | Iceland | 13.8.2014 |
| EU/1/09/605 | Temomedac | Norway | 7.8.2014 |
| EU/1/09/606 | Temozolomide Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/606 | Temozolomide Teva | Iceland | 10.9.2014 |
| EU/1/09/606 | Temozolomide Teva | Norway | 12.9.2014 |
| EU/1/09/607 | Silodyx | Liechtenstein | 31.10.2014 |
| EU/1/09/607 | Silodyx | Iceland | 25.9.2014 |
| EU/1/09/607 | Silodyx | Norway | 15.10.2014 |
| EU/1/09/608 | Urorec | Liechtenstein | 31.10.2014 |
| EU/1/09/608 | Urorec | Iceland | 25.9.2014 |
| EU/1/09/608 | Urorec | Norway | 15.10.2014 |
| EU/1/09/609 | Elonva | Liechtenstein | 31.8.2014 |
| EU/1/09/609 | Elonva | Iceland | 10.9.2014 |
| EU/1/09/609 | Elonva | Norway | 8.9.2014 |
| EU/1/09/611 | Docetaxel Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/611 | Docetaxel Teva | Iceland | 12.8.2014 |
| EU/1/09/611 | Docetaxel Teva | Norway | 6.8.2014 |
| EU/1/10/614 | Menveo | Liechtenstein | 31.12.2014 |
| EU/1/10/614 | Menveo | Iceland | 20.12.2014 |
| EU/1/10/614 | Menveo | Norway | 12.12.2014 |
| EU/1/10/616 | Temozolomide HEXAL | Liechtenstein | 31.12.2014 |
| EU/1/10/616 | Temozolomide Hexal | Iceland | 12.12.2014 |
| EU/1/10/616 | Temozolomide Hexal | Norway | 26.11.2014 |
| EU/1/10/617 | Temozolomid Sandoz | Liechtenstein | 31.12.2014 |
| EU/1/10/617 | Temozolomide Sandoz | Iceland | 16.12.2014 |
| EU/1/10/617 | Temozolomide Sandoz | Norway | 28.11.2014 |
| EU/1/10/619 | DuoPlavin | Liechtenstein | 31.12.2014 |
| EU/1/10/619 | DuoPlavin | Iceland | 18.12.2014 |
| EU/1/10/619 | DuoPlavin | Norway | 3.12.2014 |
| EU/1/10/620 | Ristfor | Liechtenstein | 31.12.2014 |
| EU/1/10/621 | Ristaben | Liechtenstein | 31.12.2014 |
| EU/1/10/622 | Tepadina | Liechtenstein | 31.12.2014 |
| EU/1/10/622 | Tepadina | Iceland | 10.12.2014 |
| EU/1/10/622 | Tepadina | Norway | 28.11.2014 |
| EU/1/10/623 | DuoCover | Liechtenstein | 31.12.2014 |
| EU/1/10/623 | DuoCover | Iceland | 18.12.2014 |
| EU/1/10/623 | DuoCover | Norway | 3.12.2014 |
| EU/1/11/710 | Votubia | Liechtenstein | 31.8.2014 |
| EU/1/11/710 | Votubia | Iceland | 12.8.2014 |
| EU/1/11/710 | Votubia | Norway | 7.8.2014 |
| EU/1/12/793 | XALKORI | Liechtenstein | 31.8.2014 |
| EU/1/12/793 | XALKORI | Iceland | 10.9.2014 |
| EU/1/12/793 | XALKORI | Norway | 5.9.2014 |
| EU/1/12/794 | ADCETRIS | Liechtenstein | 31.8.2014 |
| EU/1/12/794 | ADCETRIS | Iceland | 10.9.2014 |
| EU/1/12/794 | ADCETRIS | Norway | 5.9.2014 |
| EU/1/13/848 | Erivedge | Liechtenstein | 31.8.2014 |
| EU/1/13/848 | Erivedge | Iceland | 17.7.2014 |
| EU/1/13/848 | Erivedge | Norway | 5.8.2014 |
| EU/1/97/044 | Tasmar | Liechtenstein | 31.8.2014 |
| EU/1/97/044 | Tasmar | Iceland | 13.8.2014 |
| EU/1/97/044 | Tasmar | Norway | 13.8.2014 |
| EU/1/99/114 | Zeffix | Iceland | 18.7.2014 |
| EU/1/99/114 | Zeffix | Norway | 9.7.2014 |
| EU/1/99/123 | Renagel | Liechtenstein | 31.12.2014 |
| EU/1/99/123 | Renagel | Iceland | 17.12.2014 |
| EU/1/99/123 | Renagel | Norway | 10.12.2014 |
| EU/2/04/043 | Equilis StrepE | Norway | 10.7.2014 |
| EU/2/04/044 | Aivlosin | Liechtenstein | 31.10.2014 |
| EU/2/04/044 | Aivlosin | Iceland | 24.9.2014 |
| EU/2/04/044 | Aivlosin | Norway | 11.11.2014 |
| EU/2/08/086 | Equip WNV | Norway | 12.11.2014 |
| EU/2/08/087 | Masivet | Norway | 11.11.2014 |
| EU/2/09/094 | BTVPUR AlSap 8 | Norway | 21.7.2014 |
| EU/2/09/095 | Improvac | Norway | 11.11.2014 |
| EU/2/09/096 | Leucogen | Norway | 9.10.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Norway | 9.10.2014 |
| EU/2/09/099 | Suvaxyn PCV | Norway | 21.7.2014 |
| EU/2/09/100 | Palladia | Norway | 11.11.2014 |
| EU/2/09/100 | Palladia | Liechtenstein | 31.8.2014 |
| EU/2/09/100 | Palladia | Iceland | 15.8.2014 |
| EU/2/09/101 | Zolvix | Iceland | 4.12.2014 |
| EU/2/09/101 | Zolvix | Norway | 17.12.2014 |
| EU/2/09/102 | Gripovac 3 | Norway | 17.12.2014 |
| EU/2/09/102 | Gripovac 3 | Liechtenstein | 31.12.2014 |
| EU/2/09/102 | Gripovac 3 | Iceland | 20.12.2014 |
| EU/2/09/103 | Respiporc Flu3 | Liechtenstein | 31.12.2014 |
| EU/2/09/103 | RESPIPORC FLU3 | Iceland | 20.12.2014 |
| EU/2/09/104 | Zulvac 8 Ovis | Liechtenstein | 31.12.2014 |
| EU/2/09/104 | Zulvac 8 Ovis | Iceland | 4.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Norway | 15.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Liechtenstein | 31.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Iceland | 4.12.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/04/287

Osseor

Iceland

16.9.2014

EU/1/04/288

Protelos

Iceland

16.9.2014

EU/1/04/289

Angiox

Iceland

18.7.2014

EU/1/04/289

Angiox

Norway

8.7.2014

EU/1/04/295

Xagrid

Liechtenstein

31.8.2014

EU/1/04/295

Xagrid

Iceland

14.8.2014

EU/1/04/295

Xagrid

Norway

7.8.2014

EU/1/04/298

Kivexa

Liechtenstein

31.12.2014

EU/1/04/298

Kivexa

Iceland

10.12.2014

EU/1/04/298

Kivexa

Norway

17.12.2014

EU/1/04/299

Fendrix

Liechtenstein

31.12.2014

EU/1/04/299

Fendrix

Iceland

9.12.2014

EU/1/04/299

Fendrix

Norway

4.12.2014

EU/1/04/300

Avastin

Liechtenstein

31.12.2014

EU/1/04/300

Avastin

Iceland

12.12.2014

EU/1/04/300

Avastin

Norway

28.11.2014

EU/1/04/302

Prialt

Liechtenstein

31.10.2014

EU/1/04/302

Prialt

Iceland

24.9.2014

EU/1/04/302

Prialt

Norway

26.9.2014

EU/1/09/511

Conbriza

Iceland

16.9.2014

EU/1/09/530

Repaglinide Teva

Iceland

16.7.2014

EU/1/09/530

Repaglinide Teva

Norway

1.7.2014

EU/1/09/539

Samsca

Iceland

18.7.2014

EU/1/09/539

Samsca

Norway

1.7.2014

EU/1/09/545

Onglyza

Liechtenstein

31.8.2014

EU/1/09/545

Onglyza

Iceland

14.8.2014

EU/1/09/545

Onglyza

Norway

25.8.2014

EU/1/09/546

Simponi

Iceland

18.7.2014

EU/1/09/546

Simponi

Norway

10.7.2014

EU/1/09/550

Javlor

Iceland

22.7.2014

EU/1/09/552

Topotecan Teva

Iceland

18.7.2014

EU/1/09/552

Topotecan Teva

Norway

10.7.2014

EU/1/09/555

Clopidogrel TAD

Iceland

22.7.2014

EU/1/09/555

Clopidogrel TAD

Norway

1.7.2014

EU/1/09/559

Clopidogrel Mylan

Norway

1.7.2014

EU/1/09/560

Clopidogrel DURA

Norway

1.7.2014

EU/1/09/562

Clopidogrel Krka d.d.

Iceland

22.7.2014

EU/1/09/562

Clopidogrel Krka d.d.

Norway

1.7.2014

EU/1/09/563

ChondroCelect

Liechtenstein

31.8.2014

EU/1/09/563

ChondroCelect

Iceland

9.9.2014

EU/1/09/563

ChondroCelect

Norway

10.9.2014

EU/1/09/564

Ilaris

Iceland

18.7.2014

EU/1/09/564

Ilaris

Norway

10.7.2014

EU/1/09/565

Biopoin

Liechtenstein

31.10.2014

EU/1/09/565

Biopoin

Iceland

10.9.2014

EU/1/09/565

Biopoin

Norway

8.9.2014

EU/1/09/566

Lamivudine Teva

Liechtenstein

31.10.2014

EU/1/09/566

Lamivudine Teva

Iceland

23.9.2014

EU/1/09/566

Lamivudine Teva

Norway

9.10.2014

EU/1/09/568

Clopidogrel Apotex

Liechtenstein

31.10.2014

EU/1/09/568

Clopidogrel Apotex

Iceland

25.9.2014

EU/1/09/568

Clopidogrel Apotex

Norway

29.9.2014

EU/1/09/569

Exforge HCT

Liechtenstein

31.8.2014

EU/1/09/569

Exforge HCT

Iceland

18.7.2014

EU/1/09/569

Exforge HCT

Norway

29.7.2014

EU/1/09/572

Vantavo

Liechtenstein

31.10.2014

EU/1/09/572

Vantavo

Iceland

25.9.2014

EU/1/09/572

Vantavo

Norway

26.9.2014

EU/1/09/573

Eporatio

Liechtenstein

31.10.2014

EU/1/09/573

Eporatio

Iceland

24.9.2014

EU/1/09/573

Eporatio

Norway

29.9.2014

EU/1/09/574

Dafiro HCT

Liechtenstein

31.8.2014

EU/1/09/574

Dafiro HCT

Iceland

22.7.2014

EU/1/09/574

Dafiro HCT

Norway

4.8.2014

EU/1/09/575

Copalia HCT

Liechtenstein

31.8.2014

EU/1/09/575

Copalia HCT

Iceland

22.7.2014

EU/1/09/575

Copalia HCT

Norway

4.8.2014

EU/1/09/576

Irbesartan Teva

Liechtenstein

31.8.2014

EU/1/09/576

Irbesartan Teva

Iceland

13.8.2014

EU/1/09/576

Irbesartan Teva

Norway

4.8.2014

EU/1/09/577

Foclivia

Liechtenstein

31.8.2014

EU/1/09/577

Foclivia

Iceland

21.7.2014

EU/1/09/577

Foclivia

Norway

29.7.2014

EU/1/09/578

Adjupanrix

Liechtenstein

31.8.2014

EU/1/09/578

Adjupanrix

Iceland

14.8.2014

EU/1/09/578

Adjupanrix

Norway

13.8.2014

EU/1/09/579

Repaglinide Krka

Liechtenstein

31.10.2014

EU/1/09/579

Repaglinide Krka

Iceland

10.9.2014

EU/1/09/579

Repaglinide Krka

Norway

9.9.2014

EU/1/09/580

Enyglid

Liechtenstein

31.8.2014

EU/1/09/580

Enyglid

Iceland

9.9.2014

EU/1/09/580

Enyglid

Norway

10.9.2014

EU/1/09/581

Resolor

Norway

1.7.2014

EU/1/09/583

Irbesartan/Hydrochlorothiazid

Liechtenstein

31.12.2014

EU/1/09/583

Irbesartan/Hydrochlorothiazide Teva

Iceland

9.12.2014

EU/1/09/583

Irbesartan/Hydrochlorotiazide Teva

Norway

27.11.2014

EU/1/09/584

Sildenafil Teva

Liechtenstein

31.10.2014

EU/1/09/584

Sildenafil Teva

Iceland

23.9.2014

EU/1/09/584

Sildenafil Teva

Norway

2.10.2014

EU/1/09/585

Rivastigmine 1A Pharma

Iceland

9.9.2014

EU/1/09/585

Rivastigmine 1A Pharma

Norway

10.9.2014

EU/1/09/586

Oslif Breezhaler

Liechtenstein

31.10.2014

EU/1/09/586

Oslif Breezhaler

Iceland

25.9.2014

EU/1/09/586

Oslif Breezhaler

Norway

14.10.2014

EU/1/09/587

Olanzapine Glenmark

Liechtenstein

31.8.2014

EU/1/09/587

Olanzapine Glenmark

Iceland

9.9.2014

EU/1/09/587

Olanzapine Glenmark

Norway

10.9.2014

EU/1/09/588

Olanzapine Glenmark Europe

Liechtenstein

31.8.2014

EU/1/09/588

Olanzapine Glenmark Europe

Iceland

9.9.2014

EU/1/09/588

Olanzapine Glenmark Europe

Norway

10.9.2014

EU/1/09/589

Rivastigmine HEXAL

Liechtenstein

31.8.2014

EU/1/09/589

Rivastigmine HEXAL

Iceland

13.8.2014

EU/1/09/589

Rivastigmine Hexal

Norway

13.8.2014

EU/1/09/590

Prevenar 13

Liechtenstein

31.12.2014

EU/1/09/590

Prevenar 13

Iceland

10.10.2014

EU/1/09/590

Prevenar 13

Norway

15.10.2014

EU/1/09/591

Multaq

Norway

29.9.2014

EU/1/09/591

Multaq

Iceland

26.9.2014

EU/1/09/592

Olazax Disperzi

Liechtenstein

31.8.2014

EU/1/09/592

Olazax Disperzi

Iceland

4.9.2014

EU/1/09/592

Olazax Disperzi

Norway

27.8.2014

EU/1/09/593

Onbrez Breezhaler

Liechtenstein

31.10.2014

EU/1/09/593

Onbrez Breezhaler

Iceland

25.9.2014

EU/1/09/593

Onbrez Breezhaler

Norway

14.10.2014

EU/1/09/594

Hirobrez Breezhaler

Norway

14.10.2014

EU/1/09/594

Hirobriz Breezhaler

Liechtenstein

31.10.2014

EU/1/09/594

Hirobriz Breezhaler

Iceland

25.9.2014

EU/1/09/595

Sildenafil Actavis

Iceland

23.9.2014

EU/1/09/595

Sildenafil Actavis

Norway

1.10.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Liechtenstein

31.10.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Iceland

23.9.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Norway

9.10.2014

EU/1/09/597

Olazax

Iceland

9.9.2014

EU/1/09/597

Olazax

Norway

10.9.2014

EU/1/09/598

Nevirapine Teva

Iceland

10.9.2014

EU/1/09/598

Nevirapine Teva

Norway

9.9.2014

EU/1/09/599

Rivastigmine Sandoz

Iceland

13.8.2014

EU/1/09/599

Rivastigmine Sandoz

Norway

13.8.2014

EU/1/09/600

Zutectra

Iceland

24.9.2014

EU/1/09/600

Zutectra

Norway

15.10.2014

EU/1/09/601

Firdapse

Norway

18.12.2014

EU/1/09/602

Scintimun

Liechtenstein

31.8.2014

EU/1/09/602

Scintimun

Iceland

10.9.2014

EU/1/09/602

Scintimun

Norway

18.9.2014

EU/1/09/603

Sildenafil ratiopharm

Liechtenstein

31.10.2014

EU/1/09/603

Sildenafil ratiopharm

Iceland

23.9.2014

EU/1/09/603

Sildenafil ratiopharm

Norway

2.10.2014

EU/1/09/604

Leflunomide Winthrop

Liechtenstein

31.12.2014

EU/1/09/604

Leflunomide Winthrop

Iceland

12.12.2014

EU/1/09/604

Leflunomide Winthrop

Norway

28.11.2014

EU/1/09/605

Temomedac

Liechtenstein

31.8.2014

EU/1/09/605

Temomedac

Iceland

13.8.2014

EU/1/09/605

Temomedac

Norway

7.8.2014

EU/1/09/606

Temozolomide Teva

Liechtenstein

31.10.2014

EU/1/09/606

Temozolomide Teva

Iceland

10.9.2014

EU/1/09/606

Temozolomide Teva

Norway

12.9.2014

EU/1/09/607

Silodyx

Liechtenstein

31.10.2014

EU/1/09/607

Silodyx

Iceland

25.9.2014

EU/1/09/607

Silodyx

Norway

15.10.2014

EU/1/09/608

Urorec

Liechtenstein

31.10.2014

EU/1/09/608

Urorec

Iceland

25.9.2014

EU/1/09/608

Urorec

Norway

15.10.2014

EU/1/09/609

Elonva

Liechtenstein

31.8.2014

EU/1/09/609

Elonva

Iceland

10.9.2014

EU/1/09/609

Elonva

Norway

8.9.2014

EU/1/09/611

Docetaxel Teva

Liechtenstein

31.8.2014

EU/1/09/611

Docetaxel Teva

Iceland

12.8.2014

EU/1/09/611

Docetaxel Teva

Norway

6.8.2014

EU/1/10/614

Menveo

Liechtenstein

31.12.2014

EU/1/10/614

Menveo

Iceland

20.12.2014

EU/1/10/614

Menveo

Norway

12.12.2014

EU/1/10/616

Temozolomide HEXAL

Liechtenstein

31.12.2014

EU/1/10/616

Temozolomide Hexal

Iceland

12.12.2014

EU/1/10/616

Temozolomide Hexal

Norway

26.11.2014

EU/1/10/617

Temozolomid Sandoz

Liechtenstein

31.12.2014

EU/1/10/617

Temozolomide Sandoz

Iceland

16.12.2014

EU/1/10/617

Temozolomide Sandoz

Norway

28.11.2014

EU/1/10/619

DuoPlavin

Liechtenstein

31.12.2014

EU/1/10/619

DuoPlavin

Iceland

18.12.2014

EU/1/10/619

DuoPlavin

Norway

3.12.2014

EU/1/10/620

Ristfor

Liechtenstein

31.12.2014

EU/1/10/621

Ristaben

Liechtenstein

31.12.2014

EU/1/10/622

Tepadina

Liechtenstein

31.12.2014

EU/1/10/622

Tepadina

Iceland

10.12.2014

EU/1/10/622

Tepadina

Norway

28.11.2014

EU/1/10/623

DuoCover

Liechtenstein

31.12.2014

EU/1/10/623

DuoCover

Iceland

18.12.2014

EU/1/10/623

DuoCover

Norway

3.12.2014

EU/1/11/710

Votubia

Liechtenstein

31.8.2014

EU/1/11/710

Votubia

Iceland

12.8.2014

EU/1/11/710

Votubia

Norway

7.8.2014

EU/1/12/793

XALKORI

Liechtenstein

31.8.2014

EU/1/12/793

XALKORI

Iceland

10.9.2014

EU/1/12/793

XALKORI

Norway

5.9.2014

EU/1/12/794

ADCETRIS

Liechtenstein

31.8.2014

EU/1/12/794

ADCETRIS

Iceland

10.9.2014

EU/1/12/794

ADCETRIS

Norway

5.9.2014

EU/1/13/848

Erivedge

Liechtenstein

31.8.2014

EU/1/13/848

Erivedge

Iceland

17.7.2014

EU/1/13/848

Erivedge

Norway

5.8.2014

EU/1/97/044

Tasmar

Liechtenstein

31.8.2014

EU/1/97/044

Tasmar

Iceland

13.8.2014

EU/1/97/044

Tasmar

Norway

13.8.2014

EU/1/99/114

Zeffix

Iceland

18.7.2014

EU/1/99/114

Zeffix

Norway

9.7.2014

EU/1/99/123

Renagel

Liechtenstein

31.12.2014

EU/1/99/123

Renagel

Iceland

17.12.2014

EU/1/99/123

Renagel

Norway

10.12.2014

EU/2/04/043

Equilis StrepE

Norway

10.7.2014

EU/2/04/044

Aivlosin

Liechtenstein

31.10.2014

EU/2/04/044

Aivlosin

Iceland

24.9.2014

EU/2/04/044

Aivlosin

Norway

11.11.2014

EU/2/08/086

Equip WNV

Norway

12.11.2014

EU/2/08/087

Masivet

Norway

11.11.2014

EU/2/09/094

BTVPUR AlSap 8

Norway

21.7.2014

EU/2/09/095

Improvac

Norway

11.11.2014

EU/2/09/096

Leucogen

Norway

9.10.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Norway

9.10.2014

EU/2/09/099

Suvaxyn PCV

Norway

21.7.2014

EU/2/09/100

Palladia

Norway

11.11.2014

EU/2/09/100

Palladia

Liechtenstein

31.8.2014

EU/2/09/100

Palladia

Iceland

15.8.2014

EU/2/09/101

Zolvix

Iceland

4.12.2014

EU/2/09/101

Zolvix

Norway

17.12.2014

EU/2/09/102

Gripovac 3

Norway

17.12.2014

EU/2/09/102

Gripovac 3

Liechtenstein

31.12.2014

EU/2/09/102

Gripovac 3

Iceland

20.12.2014

EU/2/09/103

Respiporc Flu3

Liechtenstein

31.12.2014

EU/2/09/103

RESPIPORC FLU3

Iceland

20.12.2014

EU/2/09/104

Zulvac 8 Ovis

Liechtenstein

31.12.2014

EU/2/09/104

Zulvac 8 Ovis

Iceland

4.12.2014

EU/2/09/105

Zulvac 8 Bovis

Norway

15.12.2014

EU/2/09/105

Zulvac 8 Bovis

Liechtenstein

31.12.2014

EU/2/09/105

Zulvac 8 Bovis

Iceland

4.12.2014

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/01/195/028-029 | Liprolog KwikPen | Norway | 20.10.2014 |
| EU/1/03/255/009-010 | Ventavis | Iceland | 14.8.2014 |
| EU/1/03/255/009-010 | Ventavis | Norway | 7.8.2014 |
| EU/1/05/320/004 | Noxafil | Iceland | 10.10.2014 |
| EU/1/05/320/004 | Noxafil | Norway | 15.10.2014 |
| EU/1/07/436/005 | Isentress | Iceland | 11.9.2014 |
| EU/1/07/436/005 | Isentress | Norway | 10.9.2014 |
| EU/1/12/753/013-017 | Signifor | Iceland | 19.12.2014 |
| EU/1/12/753/013-017 | Signifor | Norway | 3.12.2014 |
| EU/1/12/771/007-009 | Zoledronic acid Teva | Norway | 28.10.2014 |
| EU/1/12/773/013-016 | Jakavi | Iceland | 28.10.2014 |
| EU/1/12/773/013-016 | Jakavi | Norway | 15.10.2014 |
| EU/1/96/007/039-042 | Humalog KwikPen | Norway | 20.10.2014 |
| EU/1/99/117/003-004 | Synagis | Iceland | 11.9.2014 |
| EU/1/99/117/003-004 | Synagis | Norway | 11.9.2014 |
| EU/2/03/041/006-008 | Draxxin | Iceland | 12.8.2014 |
| EU/2/03/041/006-008 | Draxxin | Norway | 18.7.2014 |
| EU/2/11/135/002-003 | Panacur AquaSol | Norway | 17.12.2014 |
| EU/2/11/135/002-003 | Panacur AquaSol | Iceland | 15.8.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/01/195/028-029

Liprolog KwikPen

Norway

20.10.2014

EU/1/03/255/009-010

Ventavis

Iceland

14.8.2014

EU/1/03/255/009-010

Ventavis

Norway

7.8.2014

EU/1/05/320/004

Noxafil

Iceland

10.10.2014

EU/1/05/320/004

Noxafil

Norway

15.10.2014

EU/1/07/436/005

Isentress

Iceland

11.9.2014

EU/1/07/436/005

Isentress

Norway

10.9.2014

EU/1/12/753/013-017

Signifor

Iceland

19.12.2014

EU/1/12/753/013-017

Signifor

Norway

3.12.2014

EU/1/12/771/007-009

Zoledronic acid Teva

Norway

28.10.2014

EU/1/12/773/013-016

Jakavi

Iceland

28.10.2014

EU/1/12/773/013-016

Jakavi

Norway

15.10.2014

EU/1/96/007/039-042

Humalog KwikPen

Norway

20.10.2014

EU/1/99/117/003-004

Synagis

Iceland

11.9.2014

EU/1/99/117/003-004

Synagis

Norway

11.9.2014

EU/2/03/041/006-008

Draxxin

Iceland

12.8.2014

EU/2/03/041/006-008

Draxxin

Norway

18.7.2014

EU/2/11/135/002-003

Panacur AquaSol

Norway

17.12.2014

EU/2/11/135/002-003

Panacur AquaSol

Iceland

15.8.2014

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/06/339 | Preotact | Iceland | 12.8.2014 |
| EU/1/06/339 | Preotact | Norway | 13.8.2014 |
| EU/1/07/426 | Olanzapine Cipla | Liechtenstein | 31.8.2014 |
| EU/1/07/426 | Olanzapine Cipla | Iceland | 22.7.2014 |
| EU/1/08/467 | Doribax | Liechtenstein | 31.8.2014 |
| EU/1/08/467 | Doribax | Iceland | 15.8.2014 |
| EU/1/08/467 | Doribax | Norway | 13.8.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Liechtenstein | 31.10.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Iceland | 10.9.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Norway | 14.10.2014 |
| EU/1/10/649 | Clopidogrel Teva Pharma B.V. | Liechtenstein | 31.10.2014 |
| EU/1/10/649 | Clopidogrel Teva Pharma B.V. | Iceland | 19.11.2014 |
| EU/1/10/661 | FLUENZ | Liechtenstein | 31.12.2014 |
| EU/1/10/661 | Fluenz | Iceland | 18.11.2014 |
| EU/1/10/661 | Fluenz | Norway | 17.12.2014 |
| EU/1/10/662 | Docetaxel Teva Pharma | Iceland | 12.8.2014 |
| EU/1/11/675 | Leflunomide Teva | Iceland | 12.8.2014 |
| EU/1/11/689 | IOA | Liechtenstein | 31.8.2014 |
| EU/1/11/689 | Ioa | Iceland | 2.9.2014 |
| EU/1/11/689 | IOA | Norway | 16.9.2014 |
| EU/1/11/723 | Pioglitazon Krka | Liechtenstein | 31.10.2014 |
| EU/1/11/723 | Pioglitazone Krka | Iceland | 24.9.2014 |
| EU/1/11/735 | Ipreziv | Liechtenstein | 31.12.2014 |
| EU/1/11/735 | Ipreziv | Iceland | 19.11.2014 |
| EU/1/11/735 | Ipreziv | Norway | 17.12.2014 |
| EU/1/11/744 | Topotecan Eagle | Liechtenstein | 31.10.2014 |
| EU/1/11/744 | Topotecan Eagle | Iceland | 27.10.2014 |
| EU/1/11/744 | Topotecan Eagle | Norway | 5.11.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Liechtenstein | 31.8.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Iceland | 4.9.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Norway | 16.9.2014 |
| EU/1/97/037 | Vistide | Liechtenstein | 31.10.2014 |
| EU/1/97/037 | Vistide | Iceland | 10.9.2014 |
| EU/1/97/043 | Revasc | Liechtenstein | 31.8.2014 |
| EU/1/97/043 | Revasc | Iceland | 14.8.2014 |
| EU/1/97/043 | Revasc | Norway | 26.8.2014 |
| EU/2/06/058 | Flexicam | Iceland | 12.8.2014 |

EU Number

Product

Country

Date of withdrawal

EU/1/06/339

Preotact

Iceland

12.8.2014

EU/1/06/339

Preotact

Norway

13.8.2014

EU/1/07/426

Olanzapine Cipla

Liechtenstein

31.8.2014

EU/1/07/426

Olanzapine Cipla

Iceland

22.7.2014

EU/1/08/467

Doribax

Liechtenstein

31.8.2014

EU/1/08/467

Doribax

Iceland

15.8.2014

EU/1/08/467

Doribax

Norway

13.8.2014

EU/1/09/557

Clopidogrel Qualimed

Liechtenstein

31.10.2014

EU/1/09/557

Clopidogrel Qualimed

Iceland

10.9.2014

EU/1/09/557

Clopidogrel Qualimed

Norway

14.10.2014

EU/1/10/649

Clopidogrel Teva Pharma B.V.

Liechtenstein

31.10.2014

EU/1/10/649

Clopidogrel Teva Pharma B.V.

Iceland

19.11.2014

EU/1/10/661

FLUENZ

Liechtenstein

31.12.2014

EU/1/10/661

Fluenz

Iceland

18.11.2014

EU/1/10/661

Fluenz

Norway

17.12.2014

EU/1/10/662

Docetaxel Teva Pharma

Iceland

12.8.2014

EU/1/11/675

Leflunomide Teva

Iceland

12.8.2014

EU/1/11/689

IOA

Liechtenstein

31.8.2014

EU/1/11/689

Ioa

Iceland

2.9.2014

EU/1/11/689

IOA

Norway

16.9.2014

EU/1/11/723

Pioglitazon Krka

Liechtenstein

31.10.2014

EU/1/11/723

Pioglitazone Krka

Iceland

24.9.2014

EU/1/11/735

Ipreziv

Liechtenstein

31.12.2014

EU/1/11/735

Ipreziv

Iceland

19.11.2014

EU/1/11/735

Ipreziv

Norway

17.12.2014

EU/1/11/744

Topotecan Eagle

Liechtenstein

31.10.2014

EU/1/11/744

Topotecan Eagle

Iceland

27.10.2014

EU/1/11/744

Topotecan Eagle

Norway

5.11.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Liechtenstein

31.8.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Iceland

4.9.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Norway

16.9.2014

EU/1/97/037

Vistide

Liechtenstein

31.10.2014

EU/1/97/037

Vistide

Iceland

10.9.2014

EU/1/97/043

Revasc

Liechtenstein

31.8.2014

EU/1/97/043

Revasc

Iceland

14.8.2014

EU/1/97/043

Revasc

Norway

26.8.2014

EU/2/06/058

Flexicam

Iceland

12.8.2014

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/13/847 | MACI | Liechtenstein | 31.12.2014 |
| EU/1/13/847 | MACI | Iceland | 19.12.2014 |

EU Number

Product

Country

Date of suspension

EU/1/13/847

MACI

Liechtenstein

31.12.2014

EU/1/13/847

MACI

Iceland

19.12.2014

---